{ "generatedAt": "2026-10-01", "offline": false, "requests": 272, "roadmaps": [ { "id": "adc-generations", "name": "ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 5, "checked": 5, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bl-b01d1-307", "name": "BL-B01D1-307", "nct": "NCT06382142", "corpus": { "status": "positive", "phase": "3", "enrolled": 418, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06382142", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 418, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-13", "completion": "2027-12", "lastUpdate": "2026-07-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast03", "name": "DESTINY-Breast03", "nct": "NCT03529110", "corpus": { "status": "positive", "phase": "3", "enrolled": 524, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03529110", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 524, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-05-21", "completion": "2026-07-30", "lastUpdate": "2025-10-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast04", "name": "DESTINY-Breast04", "nct": "NCT03734029", "corpus": { "status": "positive", "phase": "3", "enrolled": 557, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03734029", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 557, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-01-11", "completion": "2026-05-19", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ev-302", "name": "EV-302 / KEYNOTE-A39", "nct": "NCT04223856", "corpus": { "status": "positive", "phase": "3", "enrolled": 886, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04223856", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 886, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-08", "completion": "2028-03-01", "lastUpdate": "2026-05-29" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "ai-oncology-roadmap", "name": "AI in oncology roadmap: pattern readers → foundation models → agents in the workflow", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 1, "checked": 1, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "nct": "NCT04838756", "corpus": { "status": "positive", "phase": "3", "enrolled": 105934, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022.", "yearReported": 2023 }, "registry": { "nct": "NCT04838756", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 100000, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-12-07", "completion": "2025-08-12", "lastUpdate": "2026-04-02" }, "contradictions": [], "explained": [ "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." ], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "text": "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." } ] }, { "id": "ai-oncology-clinic", "name": "AI in the oncology clinic: from narrow cleared tools to multimodal decision support", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "prevention-roadmap", "name": "Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 8, "checked": 5, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "add-aspirin", "name": "Add-Aspirin", "nct": "NCT02804815", "corpus": { "status": "active", "phase": "3", "enrolled": 11000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT02804815", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-10", "completion": "2026-10", "lastUpdate": "2025-06-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "alascca", "name": "ALASCCA", "nct": "NCT02647099", "corpus": { "status": "positive", "phase": "3", "enrolled": 626, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT02647099", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 626, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-08", "completion": "2026-08", "lastUpdate": "2026-03-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "aspree", "name": "ASPREE (ASPirin in Reducing Events in the Elderly)", "nct": "NCT01038583", "corpus": { "status": "negative", "phase": "3", "enrolled": 19114, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01038583", "status": "UNKNOWN", "studyType": "OBSERVATIONAL", "enrolment": 19114, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-12", "completion": "2024-04", "lastUpdate": "2021-04-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "iarc-india-hpv-dose-study", "name": "IARC India HPV vaccine dose study (one, two or three doses)", "corpus": { "status": "positive", "phase": "observational", "enrolled": 17729, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "ken-she", "name": "KEN SHE (single-dose HPV vaccine)", "nct": "NCT03675256", "corpus": { "status": "positive", "phase": "4", "enrolled": 2275, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03675256", "status": "UNKNOWN", "phases": [ "PHASE4" ], "studyType": "INTERVENTIONAL", "enrolment": 2275, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-02-15", "completion": "2024-02-15", "lastUpdate": "2023-12-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nlst-nelson", "name": "NLST & NELSON (low-dose CT screening)", "corpus": { "status": "positive", "phase": "3", "enrolled": 53454, "enrolledBasis": "registry", "yearReported": 2011 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "nordicc", "name": "NordICC (Nordic-European Initiative on Colorectal Cancer)", "nct": "NCT00883792", "corpus": { "status": "mixed", "phase": "3", "enrolled": 84585, "enrolledBasis": "analysed", "enrolledNote": "ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care).", "yearReported": 2022 }, "registry": { "nct": "NCT00883792", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 95000, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06", "completion": "2036-07", "lastUpdate": "2017-06-19" }, "contradictions": [], "explained": [ "enrolment 84585 in the corpus (analysed), 95000 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care)." ], "papers": [] }, { "id": "osmanabad-hpv-screening", "name": "Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)", "corpus": { "status": "positive", "phase": "3", "enrolled": 131746, "enrolledBasis": "registry", "yearReported": 2009 }, "registry": null, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "nordicc", "name": "NordICC (Nordic-European Initiative on Colorectal Cancer)", "text": "enrolment 84585 in the corpus (analysed), 95000 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care)." } ] }, { "id": "cell-therapy-roadmap", "name": "Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "chemotherapy-roadmap", "name": "Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 21, "checked": 15, "contradictions": 0, "explained": 2, "papers": 2, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "apt-trial", "name": "APT (adjuvant paclitaxel-trastuzumab)", "nct": "NCT00542451", "corpus": { "status": "positive", "phase": "2", "enrolled": 406, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00542451", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 406, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-04-21", "completion": "2022-08-30", "lastUpdate": "2024-06-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-649", "name": "CheckMate 649", "nct": "NCT02872116", "corpus": { "status": "positive", "phase": "3", "enrolled": 1581, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 2,031 participants (actual) across all three arms; the Lancet 2021 primary analysis concurrently randomised 1,581 patients to nivolumab plus chemotherapy or chemotherapy alone, leaving out the nivolumab plus ipilimumab arm.", "yearReported": 2020 }, "registry": { "nct": "NCT02872116", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2031, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-05-27", "completion": "2024-06-06", "lastUpdate": "2025-08-07" }, "contradictions": [], "explained": [ "enrolment 1581 in the corpus (randomised), 2031 on the registry (actual; 22 percent apart): ClinicalTrials.gov lists 2,031 participants (actual) across all three arms; the Lancet 2021 primary analysis concurrently randomised 1,581 patients to nivolumab plus chemotherapy or chemotherapy alone, leaving out the nivolumab plus ipilimumab arm." ], "papers": [] }, { "id": "cross", "name": "CROSS", "nct": "NTR487", "corpus": { "status": "positive", "phase": "3", "enrolled": 366, "enrolledBasis": "registry", "yearReported": 2012 }, "registry": null, "contradictions": [], "explained": [], "papers": [ { "pmid": "42774476", "doi": "10.1002/fsn3.72380", "title": "<i>Citrus reticulata</i> Essential Oil as a Bioactive Food Ingredient: Composition Variability, Extraction, Functional Bioactivities, and Cross-Study Quantitative Analysis.", "journal": "Food Sci Nutr", "date": "2026-09-21" }, { "pmid": "42793307", "doi": "10.3390/cimb48090951", "title": "Shared and Disease-Preferential Matrisome Programs in Fibrosing Interstitial Lung Disease: Evidence from Cross-Cohort and Within-Cohort Analysis.", "journal": "Curr Issues Mol Biol", "date": "2026-09-17" } ] }, { "id": "destiny-breast06", "name": "DESTINY-Breast06", "nct": "NCT04494425", "corpus": { "status": "positive", "phase": "3", "enrolled": 866, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04494425", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 866, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-18", "completion": "2026-06-19", "lastUpdate": "2026-03-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "echelon-1", "name": "ECHELON-1", "nct": "NCT01712490", "corpus": { "status": "positive", "phase": "3", "enrolled": 1334, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01712490", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1334, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-04-20", "completion": "2026-02-02", "lastUpdate": "2026-02-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "eortc-26981", "name": "EORTC 26981 / NCIC CE.3 (Stupp trial)", "nct": "NCT00006353", "corpus": { "status": "positive", "phase": "3", "enrolled": 575, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": { "nct": "NCT00006353", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 575, "enrolmentType": "ACTUAL", "primaryCompletion": "2002-03", "lastUpdate": "2012-09-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ev-302", "name": "EV-302 / KEYNOTE-A39", "nct": "NCT04223856", "corpus": { "status": "positive", "phase": "3", "enrolled": 886, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04223856", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 886, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-08", "completion": "2028-03-01", "lastUpdate": "2026-05-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interlace", "name": "INTERLACE", "nct": "NCT01566240", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT01566240", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02", "completion": "2026-12", "lastUpdate": "2024-12-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-024-189", "name": "KEYNOTE-024 & KEYNOTE-189", "nct": "NCT02142738", "corpus": { "status": "positive", "phase": "3", "enrolled": 921, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT02142738", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 305, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-05-09", "completion": "2021-05-27", "lastUpdate": "2022-06-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "low-dose-nivolumab-tmh", "name": "Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 151, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "olanzapine-appetite-tmh", "name": "Low-dose olanzapine for cancer anorexia (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 124, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "metro-plus-varanasi", "name": "METRO PLUS (Tata Memorial Centre, Varanasi)", "corpus": { "status": "positive", "phase": "3", "enrolled": 238, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "napoli-3", "name": "NAPOLI 3", "nct": "NCT04083235", "corpus": { "status": "positive", "phase": "3", "enrolled": 770, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04083235", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 770, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-07-23", "completion": "2025-02-18", "lastUpdate": "2026-04-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "metronomic-vs-cisplatin-tmh", "name": "Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 422, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "polarix", "name": "POLARIX", "nct": "NCT03274492", "corpus": { "status": "positive", "phase": "3", "enrolled": 879, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 1,000 participants (actual); the NEJM 2022 primary analysis randomised 879 patients (440 Pola-R-CHP, 439 R-CHOP).", "yearReported": 2021 }, "registry": { "nct": "NCT03274492", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1000, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-04-30", "completion": "2026-04-30", "lastUpdate": "2026-05-08" }, "contradictions": [], "explained": [ "enrolment 879 in the corpus (randomised), 1000 on the registry (actual; 12 percent apart): ClinicalTrials.gov lists 1,000 participants (actual); the NEJM 2022 primary analysis randomised 879 patients (440 Pola-R-CHP, 439 R-CHOP)." ], "papers": [] }, { "id": "prodige-24", "name": "PRODIGE 24 / CCTG PA6", "nct": "NCT01526135", "corpus": { "status": "positive", "phase": "3", "enrolled": 493, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01526135", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 493, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03", "completion": "2021-07-16", "lastUpdate": "2022-01-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rathl", "name": "RATHL", "nct": "NCT00678327", "corpus": { "status": "positive", "phase": "3", "enrolled": 1214, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00678327", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1202, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-01-31", "completion": "2024-05-01", "lastUpdate": "2024-05-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rxponder", "name": "RxPONDER (SWOG S1007)", "nct": "NCT01272037", "corpus": { "status": "positive", "phase": "3", "enrolled": 5018, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01272037", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5018, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-02-01", "completion": "2027-01-08", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "scarlet-s2212", "name": "SCARLET (SWOG S2212)", "nct": "NCT05929768", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 2400, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05929768", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2400, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-03-31", "completion": "2033-04", "lastUpdate": "2025-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tailorx", "name": "TAILORx", "nct": "NCT00310180", "corpus": { "status": "positive", "phase": "3", "enrolled": 10273, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00310180", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 10273, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03-02", "completion": "2030-09-30", "lastUpdate": "2026-09-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "checkmate-649", "name": "CheckMate 649", "text": "enrolment 1581 in the corpus (randomised), 2031 on the registry (actual; 22 percent apart): ClinicalTrials.gov lists 2,031 participants (actual) across all three arms; the Lancet 2021 primary analysis concurrently randomised 1,581 patients to nivolumab plus chemotherapy or chemotherapy alone, leaving out the nivolumab plus ipilimumab arm." }, { "ref": "polarix", "name": "POLARIX", "text": "enrolment 879 in the corpus (randomised), 1000 on the registry (actual; 12 percent apart): ClinicalTrials.gov lists 1,000 participants (actual); the NEJM 2022 primary analysis randomised 879 patients (440 Pola-R-CHP, 439 R-CHOP)." } ] }, { "id": "colorectal-roadmap", "name": "Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation", "asOf": "2026-09-24", "since": "2026-09-24", "counts": { "trials": 19, "checked": 17, "contradictions": 4, "explained": 2, "papers": 0, "watch": 12, "watchPassed": 3 }, "trials": [ { "id": "atomic", "name": "ATOMIC (Alliance A021502)", "nct": "NCT02912559", "corpus": { "status": "positive", "phase": "3", "enrolled": 712, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT02912559", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 712, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-04", "completion": "2026-12-18", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "azur-1", "name": "AZUR-1", "nct": "NCT05723562", "corpus": { "status": "positive", "phase": "2", "enrolled": 154, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT05723562", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 154, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-11-02", "completion": "2029-10-11", "lastUpdate": "2026-05-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "beacon-crc", "name": "BEACON CRC", "nct": "NCT02928224", "corpus": { "status": "positive", "phase": "3", "enrolled": 665, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT02928224", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 702, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-02-11", "completion": "2022-11-10", "lastUpdate": "2023-12-21" }, "contradictions": [ "enrolment 665 in the corpus, 702 on the registry (actual; 5 percent apart)" ], "explained": [], "papers": [] }, { "id": "breakwater", "name": "BREAKWATER", "nct": "NCT04607421", "corpus": { "status": "positive", "phase": "3", "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04607421", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 841, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-01", "completion": "2027-12-28", "lastUpdate": "2026-06-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-8hw", "name": "CheckMate 8HW", "nct": "NCT04008030", "corpus": { "status": "positive", "phase": "3", "enrolled": 839, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04008030", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 839, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-08-28", "completion": "2027-03-23", "lastUpdate": "2026-08-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "codebreak-300", "name": "CodeBreaK 300", "nct": "NCT05198934", "corpus": { "status": "positive", "phase": "3", "enrolled": 160, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT05198934", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 160, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-16", "completion": "2026-04-14", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "crystal-fire3", "name": "CRYSTAL & FIRE-3", "nct": "NCT00154102", "corpus": { "status": "positive", "phase": "3", "enrolled": 1198, "enrolledBasis": "randomised", "enrolledNote": "Two trials under one record: CRYSTAL (NCT00154102) randomised 1,198 patients, 599 per arm, and FIRE-3 (NCT00433927) treated 592 patients with KRAS exon 2 wild-type tumours.", "yearReported": 2009 }, "registry": { "nct": "NCT00154102", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1221, "enrolmentType": "ACTUAL", "primaryCompletion": "2006-12", "completion": "2011-03", "lastUpdate": "2017-01-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "fresco-2", "name": "FRESCO-2", "nct": "NCT04322539", "corpus": { "status": "positive", "phase": "3", "enrolled": 691, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04322539", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 691, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-07-29", "completion": "2024-04-24", "lastUpdate": "2025-04-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-177", "name": "KEYNOTE-177", "nct": "NCT02563002", "corpus": { "status": "positive", "phase": "3", "enrolled": 307, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02563002", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 307, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-02-19", "completion": "2023-07-17", "lastUpdate": "2024-10-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mountaineer", "name": "MOUNTAINEER", "nct": "NCT03043313", "corpus": { "status": "completed", "phase": "2", "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03043313", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 117, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-03-28", "completion": "2023-11-02", "lastUpdate": "2024-11-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niche-2", "name": "NICHE-2", "nct": "NCT03026140", "corpus": { "status": "positive", "phase": "2", "enrolled": 115, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03026140", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 353, "enrolmentType": "ESTIMATED", "primaryCompletion": "2032-03-01", "completion": "2032-03-01", "lastUpdate": "2026-09-30" }, "contradictions": [], "explained": [ "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." ], "papers": [] }, { "id": "nordicc", "name": "NordICC (Nordic-European Initiative on Colorectal Cancer)", "nct": "NCT00883792", "corpus": { "status": "mixed", "phase": "3", "enrolled": 84585, "enrolledBasis": "analysed", "enrolledNote": "ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care).", "yearReported": 2022 }, "registry": { "nct": "NCT00883792", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 95000, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06", "completion": "2036-07", "lastUpdate": "2017-06-19" }, "contradictions": [], "explained": [ "enrolment 84585 in the corpus (analysed), 95000 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care)." ], "papers": [] }, { "id": "opra", "name": "OPRA", "nct": "NCT02008656", "corpus": { "status": "positive", "phase": "2", "enrolled": 324, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT02008656", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 358, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-11", "completion": "2026-11", "lastUpdate": "2026-08-24" }, "contradictions": [ "enrolment 324 in the corpus, 358 on the registry (actual; 9 percent apart)" ], "explained": [], "papers": [] }, { "id": "paradigm", "name": "PARADIGM", "nct": "NCT02394795", "corpus": { "status": "positive", "phase": "3", "enrolled": 823, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT02394795", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 823, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-01-14", "completion": "2022-01-14", "lastUpdate": "2023-11-01" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prodige-23", "name": "PRODIGE 23", "nct": "NCT01804790", "corpus": { "status": "positive", "phase": "3", "enrolled": 461, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT01804790", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 461, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-07-01", "completion": "2023-07-01", "lastUpdate": "2025-06-12" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rapido", "name": "RAPIDO", "nct": "NCT01558921", "corpus": { "status": "positive", "phase": "3", "enrolled": 920, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01558921", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 920, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-08", "completion": "2026-12-31", "lastUpdate": "2026-05-01" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "sunlight", "name": "SUNLIGHT", "nct": "NCT04737187", "corpus": { "status": "positive", "phase": "3", "enrolled": 492, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04737187", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 492, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-07-19", "completion": "2023-09-12", "lastUpdate": "2024-09-24" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "NordICC primary completion on the registry (colonoscopy screening, 95,000 participants, actual; active, not recruiting); study completion is listed as July 2036, when the 15-year mortality answer is due", "expected": "2026-06", "source": "https://clinicaltrials.gov/study/NCT00883792", "refs": [ "nordicc", "colorectal-screening", "idea-crc-screening-uptake-and-age-extension" ], "passed": true, "contradictions": [] }, { "item": "COBRA (NRG-GI005) study completion: circulating tumour DNA testing to direct treatment in stage IIA colon cancer (635 participants, actual; active, not recruiting)", "expected": "2026-06-21", "source": "https://clinicaltrials.gov/study/NCT04068103", "refs": [ "mrd-testing", "ctdna", "idea-crc-ctdna-de-escalation-beyond-stage-ii" ], "passed": true, "contradictions": [] }, { "item": "JANUS primary completion: adding irinotecan to FOLFOX after long-course radiotherapy in locally advanced rectal cancer (760 participants, actual; active, not recruiting)", "expected": "2026-09-30", "source": "https://clinicaltrials.gov/study/NCT05610163", "refs": [ "rectal-cancer", "irinotecan", "total-neoadjuvant-therapy", "idea-crc-organ-preservation-randomised-in-pmmr-rectal" ], "passed": true, "contradictions": [] }, { "item": "AZUR-1 primary completion: dostarlimab monotherapy in untreated mismatch repair-deficient locally advanced rectal cancer (154 participants, actual; active, not recruiting)", "expected": "2026-11-02", "source": "https://clinicaltrials.gov/study/NCT05723562", "refs": [ "azur-1", "dostarlimab", "organ-preservation", "msi-high-colorectal" ], "passed": false, "contradictions": [] }, { "item": "ATOMIC (Alliance A021502) study completion: adjuvant FOLFOX with or without atezolizumab in stage III mismatch repair-deficient colon cancer (712 participants, actual; active, not recruiting)", "expected": "2026-12-18", "source": "https://clinicaltrials.gov/study/NCT02912559", "refs": [ "atomic", "atezolizumab", "msi-high-colorectal" ], "passed": false, "contradictions": [] }, { "item": "Botensilimab and balstilimab in colorectal cancer, primary completion (234 participants, actual; active, not recruiting): the first randomised read on Fc-enhanced CTLA-4 blockade in microsatellite stable disease", "expected": "2027-09", "source": "https://clinicaltrials.gov/study/NCT05608044", "refs": [ "botensilimab", "balstilimab", "idea-immunotherapy-mss-crc", "idea-crc-mss-immunotherapy-by-biomarker-not-by-line" ], "passed": false, "contradictions": [] }, { "item": "MOUNTAINEER-03 primary completion: tucatinib with trastuzumab and mFOLFOX6 against standard of care in first-line HER2-positive metastatic colorectal cancer (400 estimated participants; recruiting)", "expected": "2027-12-31", "source": "https://clinicaltrials.gov/study/NCT05253651", "refs": [ "mountaineer", "tucatinib", "trastuzumab", "her2-amplified-colorectal" ], "passed": false, "contradictions": [ "MOUNTAINEER: watch item expects 2027-12-31; the registry now lists primary completion 2022-03-28 and completion 2023-11-02" ] }, { "item": "BREAKWATER study completion: encorafenib and cetuximab with or without chemotherapy in previously untreated BRAF V600E metastatic disease (841 participants, actual; active, not recruiting)", "expected": "2027-12-28", "source": "https://clinicaltrials.gov/study/NCT04607421", "refs": [ "breakwater", "encorafenib", "cetuximab", "braf-v600e-colorectal" ], "passed": false, "contradictions": [] }, { "item": "CIRCULATE-US (NRG-GI008) primary completion: adjuvant chemotherapy directed by residual disease on circulating tumour DNA (1,912 estimated participants; recruiting)", "expected": "2029-03-10", "source": "https://clinicaltrials.gov/study/NCT05174169", "refs": [ "mrd-testing", "signatera", "ctdna", "idea-crc-ctdna-de-escalation-beyond-stage-ii" ], "passed": false, "contradictions": [] }, { "item": "Perioperative dostarlimab in untreated T4N0 or stage III mismatch repair-deficient resectable colon cancer, primary completion (892 estimated participants; phase 3; recruiting)", "expected": "2029-03-19", "source": "https://clinicaltrials.gov/study/NCT05855200", "refs": [ "dostarlimab", "niche-2", "msi-high-colorectal", "organ-preservation" ], "passed": false, "contradictions": [ "NICHE-2: watch item expects 2029-03-19; the registry now lists primary completion 2032-03-01 and completion 2032-03-01" ] }, { "item": "CIRCULATE (PRODIGE 70) primary completion: circulating tumour DNA-based adjuvant decision in stage II colon cancer (1,980 estimated participants; recruiting)", "expected": "2032-03", "source": "https://clinicaltrials.gov/study/NCT04120701", "refs": [ "mrd-testing", "ctdna", "unicancer", "idea-crc-ctdna-de-escalation-beyond-stage-ii" ], "passed": false, "contradictions": [] }, { "item": "NICHE platform primary completion: neoadjuvant checkpoint inhibition and novel combinations in early-stage colon cancer (353 estimated participants; recruiting)", "expected": "2032-03-01", "source": "https://clinicaltrials.gov/study/NCT03026140", "refs": [ "niche-2", "nivolumab", "ipilimumab", "nki", "myriam-chalabi" ], "passed": false, "contradictions": [] } ], "contradictions": [ { "ref": "beacon-crc", "name": "BEACON CRC", "text": "enrolment 665 in the corpus, 702 on the registry (actual; 5 percent apart)" }, { "ref": "opra", "name": "OPRA", "text": "enrolment 324 in the corpus, 358 on the registry (actual; 9 percent apart)" }, { "ref": "mountaineer", "name": "MOUNTAINEER-03 primary completion: tucatinib with trastuzumab and mFOLFOX6 against standard of care in first-line HER2-positive metastatic colorectal cancer (400 estimated participants; recruiting)", "text": "MOUNTAINEER: watch item expects 2027-12-31; the registry now lists primary completion 2022-03-28 and completion 2023-11-02" }, { "ref": "dostarlimab", "name": "Perioperative dostarlimab in untreated T4N0 or stage III mismatch repair-deficient resectable colon cancer, primary completion (892 estimated participants; phase 3; recruiting)", "text": "NICHE-2: watch item expects 2029-03-19; the registry now lists primary completion 2032-03-01 and completion 2032-03-01" } ], "explained": [ { "ref": "niche-2", "name": "NICHE-2", "text": "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." }, { "ref": "nordicc", "name": "NordICC (Nordic-European Initiative on Colorectal Cancer)", "text": "enrolment 84585 in the corpus (analysed), 95000 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care)." } ] }, { "id": "ctdna-tests", "name": "ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment", "asOf": "2026-09-21", "since": "2026-09-21", "counts": { "trials": 12, "checked": 10, "contradictions": 0, "explained": 0, "papers": 2, "watch": 11, "watchPassed": 3 }, "trials": [ { "id": "bespoke-crc", "name": "BESPOKE CRC", "nct": "NCT04264702", "corpus": { "status": "active", "phase": "observational", "enrolled": 1788, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04264702", "status": "UNKNOWN", "studyType": "OBSERVATIONAL", "enrolment": 1788, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-09", "completion": "2025-09", "lastUpdate": "2023-12-12" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-us", "name": "CIRCULATE-US", "nct": "NCT05174169", "corpus": { "status": "recruiting", "phase": "2/3", "enrolled": 1912, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05174169", "status": "RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1912, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-03-10", "completion": "2030-03-10", "lastUpdate": "2026-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "eclipse-shield", "name": "ECLIPSE (Shield blood test)", "nct": "NCT04136002", "corpus": { "status": "positive", "phase": "observational", "enrolled": 44467, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04136002", "status": "ACTIVE_NOT_RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 44467, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-20", "completion": "2027-08-05", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "imvigor011", "name": "IMvigor011", "nct": "NCT04660344", "corpus": { "status": "positive", "phase": "3", "enrolled": 761, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04660344", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 761, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-15", "completion": "2026-10-01", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mermaid-1", "name": "MERMAID-1", "nct": "NCT04385368", "corpus": { "status": "completed", "phase": "3", "enrolled": 89, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04385368", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 89, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-31", "completion": "2023-08-31", "lastUpdate": "2024-08-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mermaid-2", "name": "MERMAID-2", "nct": "NCT04642469", "corpus": { "status": "completed", "phase": "3", "enrolled": 30, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04642469", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 30, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-05-31", "completion": "2024-01-15", "lastUpdate": "2024-06-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nhs-galleri", "name": "NHS-Galleri", "nct": "NCT05611632", "corpus": { "status": "active", "phase": "3", "enrolled": 142250, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov NCT05611632 and ISRCTN91431511 list 142,318 participants (actual); the Nature Medicine test-performance paper reports 142,250 participants randomised 1:1.", "yearReported": 2026 }, "registry": { "nct": "NCT05611632", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 142318, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06-12", "completion": "2031-01", "lastUpdate": "2026-07-10" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42773209", "doi": "10.1038/s41591-026-04652-8", "title": "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.", "journal": "Nat Med", "date": "2026-09-22" } ] }, { "id": "pathfinder-2", "name": "PATHFINDER 2", "nct": "NCT05155605", "corpus": { "status": "active", "phase": "observational", "enrolled": 35883, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05155605", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 35883, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02-11", "completion": "2028-04-30", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42773207", "doi": "10.1038/s41591-026-04618-w", "title": "Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.", "journal": "Nat Med", "date": "2026-09-22" } ] }, { "id": "tracc", "name": "TRACC", "nct": "NCT04050345", "corpus": { "status": "recruiting", "phase": "observational", "enrolled": 1000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04050345", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 1000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-07-31", "completion": "2031-07-31", "lastUpdate": "2024-06-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "vanguard-study", "name": "Vanguard Study (NCI Cancer Screening Research Network)", "nct": "NCT06995898", "corpus": { "status": "recruiting", "phase": "platform", "enrolled": 24000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06995898", "status": "RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 24000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-01-31", "completion": "2029-06-30", "lastUpdate": "2026-09-02" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "FDA Molecular and Clinical Genetics Panel reviews the Galleri premarket approval application", "expected": "2026-09-23", "source": "https://grail.com/press-releases/grail-announces-fda-advisory-committee-meeting-to-review-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/", "refs": [ "galleri", "grail", "mced" ], "passed": true, "contradictions": [] }, { "item": "IMvigor011 study completion on the registry; longer follow-up of ctDNA-negative patients under surveillance", "expected": "2026-10-01", "source": "https://clinicaltrials.gov/study/NCT04660344", "refs": [ "imvigor011", "atezolizumab" ], "passed": false, "contradictions": [] }, { "item": "NHS-Galleri: peer-reviewed test-performance paper (reported: Nature Medicine, 22 September 2026, states the primary endpoint was not met and is reported elsewhere)", "expected": "2026-09-22", "source": "https://doi.org/10.1038/s41591-026-04652-8", "refs": [ "nhs-galleri", "galleri", "stage-shift", "paper-nhs-galleri-performance-nat-med-2026" ], "passed": true, "contradictions": [] }, { "item": "NHS-Galleri: primary-endpoint paper (stage III/IV incidence) not yet on Europe PMC; registry study completion, with cancer-specific mortality follow-up, listed as January 2031", "expected": "2031-01", "source": "https://clinicaltrials.gov/study/NCT05611632", "refs": [ "nhs-galleri", "galleri", "stage-shift" ], "passed": false, "contradictions": [] }, { "item": "ECLIPSE (Shield) study completion on the registry", "expected": "2027-08-05", "source": "https://clinicaltrials.gov/study/NCT04136002", "refs": [ "eclipse-shield", "shield" ], "passed": false, "contradictions": [] }, { "item": "PATHFINDER 2 study completion (primary completion listed as 2026-02-11)", "expected": "2028-04-30", "source": "https://clinicaltrials.gov/study/NCT05155605", "refs": [ "pathfinder-2", "galleri" ], "passed": false, "contradictions": [] }, { "item": "Vanguard study primary completion: the NCI's randomised feasibility trial of multi-cancer detection tests in 24,000 people", "expected": "2029-01-31", "source": "https://clinicaltrials.gov/study/NCT06995898", "refs": [ "vanguard-study", "nci" ], "passed": false, "contradictions": [] }, { "item": "CIRCULATE-US primary completion: ctDNA-guided escalation and de-escalation of adjuvant chemotherapy in stage III colon cancer", "expected": "2029-03-10", "source": "https://clinicaltrials.gov/study/NCT05174169", "refs": [ "circulate-us", "signatera" ], "passed": false, "contradictions": [] }, { "item": "TRACC primary completion: 1,000 people with early colorectal cancer followed by ctDNA", "expected": "2029-07-31", "source": "https://clinicaltrials.gov/study/NCT04050345", "refs": [ "tracc" ], "passed": false, "contradictions": [] }, { "item": "VEGA (CIRCULATE-Japan): non-inferiority of no chemotherapy in ctDNA-negative colon cancer; no readout date in the sources read", "source": "https://europepmc.org/article/MED/33931919", "refs": [ "circulate-japan" ], "passed": false, "contradictions": [] }, { "item": "BESPOKE CRC: registry status not updated since a listed completion of September 2025; watch for the primary publication", "expected": "2025-09", "source": "https://clinicaltrials.gov/study/NCT04264702", "refs": [ "bespoke-crc", "signatera" ], "passed": true, "contradictions": [] } ], "contradictions": [], "explained": [] }, { "id": "devices-roadmap", "name": "Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 4, "checked": 4, "contradictions": 0, "explained": 0, "papers": 1, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ef-14", "name": "EF-14", "nct": "NCT00916409", "corpus": { "status": "positive", "phase": "3", "enrolled": 695, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00916409", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 700, "enrolmentType": "ESTIMATED", "primaryCompletion": "2016-12", "completion": "2017-03", "lastUpdate": "2017-04-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "panova-3", "name": "PANOVA-3", "nct": "NCT03377491", "corpus": { "status": "positive", "phase": "3", "enrolled": 571, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT03377491", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 571, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-16", "completion": "2024-10-16", "lastUpdate": "2026-01-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "stellar", "name": "STELLAR", "nct": "NCT02397928", "corpus": { "status": "positive", "phase": "2", "enrolled": 82, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT02397928", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 82, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-04", "completion": "2018-04", "lastUpdate": "2018-09-25" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42789827", "doi": "10.1200/jco-26-02343", "title": "Erratum: Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial.", "journal": "J Clin Oncol", "date": "2026-09-25" } ] }, { "id": "sunrise-1", "name": "SunRISe-1", "nct": "NCT04640623", "corpus": { "status": "positive", "phase": "2", "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04640623", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 220, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-03", "completion": "2027-09-30", "lastUpdate": "2026-09-25" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "diagnostics-roadmap", "name": "Diagnostics roadmap: stains → gene panels → blood tests that decide treatment", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 8, "checked": 6, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "imvigor011", "name": "IMvigor011", "nct": "NCT04660344", "corpus": { "status": "positive", "phase": "3", "enrolled": 761, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04660344", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 761, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-15", "completion": "2026-10-01", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "insight-gist", "name": "INSIGHT", "nct": "NCT05734105", "corpus": { "status": "active", "phase": "3", "enrolled": 54, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05734105", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 54, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12", "completion": "2028-12", "lastUpdate": "2025-12-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "nct": "NCT04838756", "corpus": { "status": "positive", "phase": "3", "enrolled": 105934, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022.", "yearReported": 2023 }, "registry": { "nct": "NCT04838756", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 100000, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-12-07", "completion": "2025-08-12", "lastUpdate": "2026-04-02" }, "contradictions": [], "explained": [ "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." ], "papers": [] }, { "id": "rxponder", "name": "RxPONDER (SWOG S1007)", "nct": "NCT01272037", "corpus": { "status": "positive", "phase": "3", "enrolled": 5018, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01272037", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5018, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-02-01", "completion": "2027-01-08", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-09-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tailorx", "name": "TAILORx", "nct": "NCT00310180", "corpus": { "status": "positive", "phase": "3", "enrolled": 10273, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00310180", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 10273, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03-02", "completion": "2030-09-30", "lastUpdate": "2026-09-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "text": "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." } ] }, { "id": "nutrition-lifestyle-roadmap", "name": "Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 10, "checked": 8, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "bwel", "name": "BWEL (Breast Cancer Weight Loss, Alliance A011401)", "nct": "NCT02750826", "corpus": { "status": "mixed", "phase": "3", "enrolled": 3181, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT02750826", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 3177, "enrolmentType": "ACTUAL", "primaryCompletion": "2030-05-30", "completion": "2030-05-30", "lastUpdate": "2026-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "challenge", "name": "CHALLENGE (CCTG CO.21)", "nct": "NCT00819208", "corpus": { "status": "positive", "phase": "3", "enrolled": 889, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT00819208", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 889, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-07", "completion": "2026-03-17", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ergo2", "name": "ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma", "nct": "NCT01754350", "corpus": { "status": "negative", "phase": "2", "enrolled": 50, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01754350", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 50, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-12", "completion": "2019-03", "lastUpdate": "2021-06-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "fmt-pd1-refractory-melanoma-pitt", "name": "FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)", "nct": "NCT03341143", "corpus": { "status": "completed", "phase": "2", "enrolled": 15, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists 20 participants (actual); the Science 2021 paper reports outcomes for the 15 patients who received FMT plus pembrolizumab.", "yearReported": 2021 }, "registry": { "nct": "NCT03341143", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 20, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-09-30", "completion": "2024-09-30", "lastUpdate": "2024-10-30" }, "contradictions": [], "explained": [ "enrolment 15 in the corpus (treated), 20 on the registry (actual; 25 percent apart): ClinicalTrials.gov lists 20 participants (actual); the Science 2021 paper reports outcomes for the 15 patients who received FMT plus pembrolizumab." ], "papers": [] }, { "id": "olanzapine-appetite-tmh", "name": "Low-dose olanzapine for cancer anorexia (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 124, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "mimic-01", "name": "MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma", "nct": "NCT03772899", "corpus": { "status": "active", "phase": "1", "enrolled": 20, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03772899", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1" ], "studyType": "INTERVENTIONAL", "enrolment": 20, "enrolmentType": "ESTIMATED", "primaryCompletion": "2021-09-14", "completion": "2026-08", "lastUpdate": "2025-03-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ponsegromab-phase-2", "name": "Ponsegromab phase 2 in cancer cachexia", "nct": "NCT05546476", "corpus": { "status": "positive", "phase": "2", "enrolled": 187, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05546476", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 187, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-13", "completion": "2025-04-23", "lastUpdate": "2026-06-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prehab-trial", "name": "PREHAB: multimodal prehabilitation before colorectal cancer surgery", "corpus": { "status": "positive", "phase": "3", "enrolled": 251, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "vital", "name": "VITAL (VITamin D and OmegA-3 TriaL)", "nct": "NCT01169259", "corpus": { "status": "negative", "phase": "3", "enrolled": 25871, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01169259", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 25871, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-11-10", "completion": "2026-10", "lastUpdate": "2026-07-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "whel", "name": "WHEL (Women's Healthy Eating and Living)", "nct": "NCT00003787", "corpus": { "status": "negative", "phase": "3", "enrolled": 3088, "enrolledBasis": "registry", "yearReported": 2007 }, "registry": { "nct": "NCT00003787", "status": "COMPLETED", "studyType": "OBSERVATIONAL", "enrolment": 3088, "enrolmentType": "ACTUAL", "primaryCompletion": "2007-03", "completion": "2018-12-31", "lastUpdate": "2019-06-10" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "fmt-pd1-refractory-melanoma-pitt", "name": "FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)", "text": "enrolment 15 in the corpus (treated), 20 on the registry (actual; 25 percent apart): ClinicalTrials.gov lists 20 participants (actual); the Science 2021 paper reports outcomes for the 15 patients who received FMT plus pembrolizumab." } ] }, { "id": "drug-discovery-roadmap", "name": "Drug discovery roadmap: screening in mice → maps of dependency → designing in silico", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "early-detection-roadmap", "name": "Early detection roadmap: organ screening → blood tests for many cancers", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 2, "checked": 2, "contradictions": 0, "explained": 0, "papers": 2, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "nhs-galleri", "name": "NHS-Galleri", "nct": "NCT05611632", "corpus": { "status": "active", "phase": "3", "enrolled": 142250, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov NCT05611632 and ISRCTN91431511 list 142,318 participants (actual); the Nature Medicine test-performance paper reports 142,250 participants randomised 1:1.", "yearReported": 2026 }, "registry": { "nct": "NCT05611632", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 142318, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06-12", "completion": "2031-01", "lastUpdate": "2026-07-10" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42773209", "doi": "10.1038/s41591-026-04652-8", "title": "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.", "journal": "Nat Med", "date": "2026-09-22" } ] }, { "id": "pathfinder-2", "name": "PATHFINDER 2", "nct": "NCT05155605", "corpus": { "status": "active", "phase": "observational", "enrolled": 35883, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05155605", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 35883, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02-11", "completion": "2028-04-30", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42773207", "doi": "10.1038/s41591-026-04618-w", "title": "Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.", "journal": "Nat Med", "date": "2026-09-22" } ] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "epigenetics-roadmap", "name": "Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 7, "checked": 7, "contradictions": 0, "explained": 2, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "agile", "name": "AGILE", "nct": "NCT03173248", "corpus": { "status": "positive", "phase": "3", "enrolled": 146, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03173248", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 146, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-03-18", "completion": "2026-06-30", "lastUpdate": "2026-06-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "augment-101", "name": "AUGMENT-101", "nct": "NCT04065399", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 94, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists an estimated 447 participants for the whole phase 1/2 programme, which is still recruiting; the JCO 2024 KMT2A-rearranged analysis treated 94 patients between October 2021 and July 2023 (57 efficacy-evaluable).", "yearReported": 2024 }, "registry": { "nct": "NCT04065399", "status": "RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 447, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12-15", "completion": "2027-12-15", "lastUpdate": "2026-09-16" }, "contradictions": [], "explained": [ "enrolment 94 in the corpus (treated), 447 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 447 participants for the whole phase 1/2 programme, which is still recruiting; the JCO 2024 KMT2A-rearranged analysis treated 94 patients between October 2021 and July 2023 (57 efficacy-evaluable)." ], "papers": [] }, { "id": "claridhy", "name": "ClarIDHy", "nct": "NCT02989857", "corpus": { "status": "positive", "phase": "3", "enrolled": 187, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02989857", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 187, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-01-31", "completion": "2021-05-17", "lastUpdate": "2024-08-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "golseek-1", "name": "GOLSEEK-1", "nct": "NCT06356129", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT06356129", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 850, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-08-09", "completion": "2029-06-26", "lastUpdate": "2026-07-06" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "komet-001", "name": "KOMET-001", "nct": "NCT04067336", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 112, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists an estimated 263 participants for the phase 1/2 study; 112 is the FDA efficacy population at 600 mg quoted in the approval coverage, while the JCO 2025 phase 2 paper reports 92 patients treated between January 2023 and May 2024.", "yearReported": 2025 }, "registry": { "nct": "NCT04067336", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 263, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-10-16", "completion": "2028-10-16", "lastUpdate": "2026-05-13" }, "contradictions": [], "explained": [ "enrolment 112 in the corpus (treated), 263 on the registry (estimated; 57 percent apart): ClinicalTrials.gov lists an estimated 263 participants for the phase 1/2 study; 112 is the FDA efficacy population at 600 mg quoted in the approval coverage, while the JCO 2025 phase 2 paper reports 92 patients treated between January 2023 and May 2024." ], "papers": [] }, { "id": "mevpro-1", "name": "MEVPRO-1", "nct": "NCT06551324", "corpus": { "status": "active", "phase": "3", "enrolled": 600, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06551324", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-12-28", "completion": "2028-10-29", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "viale-a", "name": "VIALE-A", "nct": "NCT02993523", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02993523", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-12-01", "completion": "2026-06-15", "lastUpdate": "2026-06-11" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "augment-101", "name": "AUGMENT-101", "text": "enrolment 94 in the corpus (treated), 447 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 447 participants for the whole phase 1/2 programme, which is still recruiting; the JCO 2024 KMT2A-rearranged analysis treated 94 patients between October 2021 and July 2023 (57 efficacy-evaluable)." }, { "ref": "komet-001", "name": "KOMET-001", "text": "enrolment 112 in the corpus (treated), 263 on the registry (estimated; 57 percent apart): ClinicalTrials.gov lists an estimated 263 participants for the phase 1/2 study; 112 is the FDA efficacy population at 600 mg quoted in the approval coverage, while the JCO 2025 phase 2 paper reports 92 patients treated between January 2023 and May 2024." } ] }, { "id": "gallbladder-cancer-roadmap", "name": "Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials", "asOf": "2026-09-24", "since": "2026-09-24", "counts": { "trials": 16, "checked": 15, "contradictions": 3, "explained": 0, "papers": 0, "watch": 10, "watchPassed": 3 }, "trials": [ { "id": "abc-02", "name": "ABC-02", "nct": "NCT00262769", "corpus": { "status": "positive", "phase": "3", "enrolled": 410, "enrolledBasis": "registry", "yearReported": 2010 }, "registry": { "nct": "NCT00262769", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 324, "enrolmentType": "ACTUAL", "primaryCompletion": "2008-08", "lastUpdate": "2012-07-17" }, "contradictions": [ "enrolment 410 in the corpus, 324 on the registry (actual; 27 percent apart)" ], "explained": [], "papers": [] }, { "id": "abc-06", "name": "ABC-06", "nct": "NCT01926236", "corpus": { "status": "positive", "phase": "3", "enrolled": 162, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT01926236", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 162, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-01-05", "completion": "2019-01", "lastUpdate": "2020-01-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "acticca-1", "name": "ACTICCA-1", "nct": "NCT02170090", "corpus": { "status": "active", "phase": "3", "enrolled": 789, "enrolledBasis": "registry" }, "registry": { "nct": "NCT02170090", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 789, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-12", "completion": "2025-12", "lastUpdate": "2025-03-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bilcap", "name": "BILCAP", "nct": "ISRCTN72785446", "corpus": { "status": "mixed", "phase": "3", "enrolled": 447, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-pantumor02", "name": "DESTINY-PanTumor02", "nct": "NCT04482309", "corpus": { "status": "positive", "phase": "2", "enrolled": 267, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04482309", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 477, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-03-23", "completion": "2027-03-23", "lastUpdate": "2026-07-10" }, "contradictions": [ "enrolment 267 in the corpus, 477 on the registry (actual; 44 percent apart)" ], "explained": [], "papers": [] }, { "id": "gain-igbc", "name": "GAIN (AIO/CALGP/ACO)", "nct": "NCT03673072", "corpus": { "status": "completed", "phase": "3", "enrolled": 68, "enrolledBasis": "registry" }, "registry": { "nct": "NCT03673072", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 68, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-10", "completion": "2024-10-10", "lastUpdate": "2024-11-12" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "herizon-btc-01", "name": "HERIZON-BTC-01", "nct": "NCT04466891", "corpus": { "status": "positive", "phase": "2", "enrolled": 87, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04466891", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 87, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-07-28", "completion": "2024-07-11", "lastUpdate": "2025-09-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "herizon-btc-302", "name": "HERIZON-BTC-302", "nct": "NCT06282575", "corpus": { "status": "recruiting", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT06282575", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 286, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-12-01", "completion": "2030-04-01", "lastUpdate": "2026-09-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-966", "name": "KEYNOTE-966", "nct": "NCT04003636", "corpus": { "status": "positive", "phase": "3", "enrolled": 1069, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04003636", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1069, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-12-15", "completion": "2025-04-01", "lastUpdate": "2026-03-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "naliricc", "name": "NALIRICC (AIO)", "nct": "NCT03043547", "corpus": { "status": "negative", "phase": "2", "enrolled": 100, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03043547", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 100, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-12-08", "completion": "2022-03-08", "lastUpdate": "2022-05-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nifty", "name": "NIFTY", "nct": "NCT03524508", "corpus": { "status": "positive", "phase": "2", "enrolled": 178, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03524508", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 178, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-09-30", "completion": "2021-12-31", "lastUpdate": "2022-08-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "opt-in", "name": "OPT-IN (EA2197)", "nct": "NCT04559139", "corpus": { "status": "active", "phase": "2/3", "enrolled": 186, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04559139", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 186, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-07-01", "completion": "2029-06-30", "lastUpdate": "2026-09-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "polcagb", "name": "POLCAGB", "nct": "NCT02867865", "corpus": { "status": "active", "phase": "2/3", "enrolled": 124, "enrolledBasis": "registry" }, "registry": { "nct": "NCT02867865", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 124, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-09-10", "completion": "2027-09-10", "lastUpdate": "2025-03-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct06109779", "name": "Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)", "nct": "NCT06109779", "corpus": { "status": "active", "phase": "3", "enrolled": 760, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06109779", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 760, "enrolmentType": "ACTUAL", "primaryCompletion": "2029-01-02", "completion": "2030-05-03", "lastUpdate": "2026-07-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "swog-s0809", "name": "SWOG S0809", "nct": "NCT00789958", "corpus": { "status": "completed", "phase": "2", "enrolled": 105, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00789958", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 105, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-12", "completion": "2017-12", "lastUpdate": "2018-04-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "topaz-1", "name": "TOPAZ-1", "nct": "NCT03875235", "corpus": { "status": "positive", "phase": "3", "enrolled": 685, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03875235", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 810, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-11", "completion": "2027-05-16", "lastUpdate": "2026-08-26" }, "contradictions": [ "enrolment 685 in the corpus, 810 on the registry (actual; 15 percent apart)" ], "explained": [], "papers": [] } ], "watch": [ { "item": "ACTICCA-1 primary completion: adjuvant gemcitabine-cisplatin vs capecitabine after resection of cholangiocarcinoma and muscle-invasive gallbladder cancer (789 patients; status active, not recruiting)", "expected": "2025-12", "source": "https://clinicaltrials.gov/study/NCT02170090", "refs": [ "acticca-1", "bilcap", "capecitabine", "gemcitabine-cisplatin" ], "passed": true, "contradictions": [] }, { "item": "GAIN: primary publication of the closed German trial of neoadjuvant gemcitabine-cisplatin before re-resection of incidental gallbladder cancer (completed 10 October 2024 with 68 participants)", "expected": "2024-10-10", "source": "https://clinicaltrials.gov/study/NCT03673072", "refs": [ "gain-igbc", "incidental-gallbladder-cancer" ], "passed": true, "contradictions": [] }, { "item": "POLCAGB primary completion: neoadjuvant chemoradiation vs chemotherapy in locally advanced gallbladder cancer (124 participants; study completion listed as 10 September 2027)", "expected": "2025-09-10", "source": "https://clinicaltrials.gov/study/NCT02867865", "refs": [ "polcagb", "chemoradiation" ], "passed": true, "contradictions": [] }, { "item": "TOPAZ-1 study completion on the registry (durvalumab plus gemcitabine-cisplatin, first line)", "expected": "2027-05-16", "source": "https://clinicaltrials.gov/study/NCT03875235", "refs": [ "topaz-1", "durvalumab" ], "passed": false, "contradictions": [] }, { "item": "DESTINY-PanTumor02 study completion (trastuzumab deruxtecan in HER2-expressing tumours including biliary)", "expected": "2027-03-23", "source": "https://clinicaltrials.gov/study/NCT04482309", "refs": [ "destiny-pantumor02", "trastuzumab-deruxtecan" ], "passed": false, "contradictions": [] }, { "item": "OPT-IN (EA2197) primary completion: perioperative vs adjuvant chemotherapy for incidental gallbladder cancer (186 estimated participants)", "expected": "2028-07-01", "source": "https://clinicaltrials.gov/study/NCT04559139", "refs": [ "opt-in", "incidental-gallbladder-cancer" ], "passed": false, "contradictions": [] }, { "item": "HERIZON-BTC-302 primary completion: first-line zanidatamab with standard of care in HER2-positive biliary tract cancer (286 estimated participants)", "expected": "2028-12-01", "source": "https://clinicaltrials.gov/study/NCT06282575", "refs": [ "herizon-btc-302", "zanidatamab", "her2" ], "passed": false, "contradictions": [] }, { "item": "ARTEMIDE-Biliary01 primary completion: adjuvant rilvegostomig plus chemotherapy after resection of biliary tract cancer (760 participants)", "expected": "2029-01-02", "source": "https://clinicaltrials.gov/study/NCT06109779", "refs": [ "nct06109779", "rilvegostomig" ], "passed": false, "contradictions": [] }, { "item": "Chile: a redesign or formal evaluation of the GES preventive cholecystectomy programme, as its 2024 evaluation recommends; no date in the sources read", "source": "https://europepmc.org/article/MED/40052976", "refs": [ "prophylactic-cholecystectomy" ], "passed": false, "contradictions": [] }, { "item": "A trial that acts on a positive residual disease blood test after biliary resection; none found on ClinicalTrials.gov or Europe PMC on 24 September 2026", "source": "https://europepmc.org/article/MED/42583118", "refs": [ "mrd-testing", "idea-gbc-ctdna-residual-disease-guided-adjuvant-trial" ], "passed": false, "contradictions": [] } ], "contradictions": [ { "ref": "abc-02", "name": "ABC-02", "text": "enrolment 410 in the corpus, 324 on the registry (actual; 27 percent apart)" }, { "ref": "destiny-pantumor02", "name": "DESTINY-PanTumor02", "text": "enrolment 267 in the corpus, 477 on the registry (actual; 44 percent apart)" }, { "ref": "topaz-1", "name": "TOPAZ-1", "text": "enrolment 685 in the corpus, 810 on the registry (actual; 15 percent apart)" } ], "explained": [] }, { "id": "global-access-roadmap", "name": "Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 17, "checked": 6, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "nct": "NCT00193765", "corpus": { "status": "positive", "phase": "3", "enrolled": 596, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed.", "yearReported": 2015 }, "registry": { "nct": "NCT00193765", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 710, "enrolmentType": "ESTIMATED", "primaryCompletion": "2019-06", "completion": "2019-06", "lastUpdate": "2017-06-16" }, "contradictions": [], "explained": [ "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." ], "papers": [] }, { "id": "harmoni-2", "name": "HARMONi-2", "nct": "NCT05499390", "corpus": { "status": "positive", "phase": "3", "enrolled": 398, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05499390", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 398, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-29", "completion": "2026-12-31", "lastUpdate": "2026-03-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "iarc-india-hpv-dose-study", "name": "IARC India HPV vaccine dose study (one, two or three doses)", "corpus": { "status": "positive", "phase": "observational", "enrolled": 17729, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "imagine-varnimcabtagene", "name": "IMAGINE (varnimcabtagene autoleucel, Immuneel)", "corpus": { "status": "positive", "phase": "2", "enrolled": 24, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "interlace", "name": "INTERLACE", "nct": "NCT01566240", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT01566240", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02", "completion": "2026-12", "lastUpdate": "2024-12-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ken-she", "name": "KEN SHE (single-dose HPV vaccine)", "nct": "NCT03675256", "corpus": { "status": "positive", "phase": "4", "enrolled": 2275, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03675256", "status": "UNKNOWN", "phases": [ "PHASE4" ], "studyType": "INTERVENTIONAL", "enrolment": 2275, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-02-15", "completion": "2024-02-15", "lastUpdate": "2023-12-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "kerala-oral-screening", "name": "Kerala oral cancer visual screening trial (Trivandrum)", "corpus": { "status": "positive", "phase": "3", "enrolled": 191873, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "low-dose-nivolumab-tmh", "name": "Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 151, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "metro-plus-varanasi", "name": "METRO PLUS (Tata Memorial Centre, Varanasi)", "corpus": { "status": "positive", "phase": "3", "enrolled": 238, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "mumbai-via-screening", "name": "Mumbai VIA cervical screening trial (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 151538, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "metronomic-vs-cisplatin-tmh", "name": "Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 422, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "orient-11", "name": "ORIENT-11", "nct": "NCT03607539", "corpus": { "status": "positive", "phase": "3", "enrolled": 397, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03607539", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 397, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-11-15", "completion": "2022-05-31", "lastUpdate": "2026-05-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "osmanabad-hpv-screening", "name": "Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)", "corpus": { "status": "positive", "phase": "3", "enrolled": 131746, "enrolledBasis": "registry", "yearReported": 2009 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "persephone", "name": "PERSEPHONE", "nct": "NCT00712140", "corpus": { "status": "positive", "phase": "3", "enrolled": 4088, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT00712140", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 4000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2011-10", "lastUpdate": "2011-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "reliance", "name": "RELIANCE", "corpus": { "status": "positive", "phase": "2", "enrolled": 59, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "progesterone-preop-tmh", "name": "Single-injection depot progesterone before breast surgery (Tata Memorial)", "corpus": { "status": "mixed", "phase": "3", "enrolled": 976, "enrolledBasis": "registry", "yearReported": 2011 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "talicel-phase-1-2", "name": "Talicabtagene autoleucel (NexCAR19) phase 1/2", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 64, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": null, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "text": "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." } ] }, { "id": "hormonal-therapy-roadmap", "name": "Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 32, "checked": 32, "contradictions": 0, "explained": 5, "papers": 2, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "arasens", "name": "ARASENS", "nct": "NCT02799602", "corpus": { "status": "positive", "phase": "3", "enrolled": 1306, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT02799602", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1306, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-10-25", "completion": "2023-04-11", "lastUpdate": "2025-12-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "arches", "name": "ARCHES", "nct": "NCT02677896", "corpus": { "status": "positive", "phase": "3", "enrolled": 1150, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT02677896", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1150, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-10-14", "completion": "2024-07-31", "lastUpdate": "2025-10-24" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42791604", "doi": "10.1002/cncr.70615", "title": "External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.", "journal": "Cancer", "date": "2026-10-01" } ] }, { "id": "cambria", "name": "CAMBRIA-1 & CAMBRIA-2", "nct": "NCT05952557", "corpus": { "status": "active", "phase": "3", "enrolled": 10000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05952557", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5511, "enrolmentType": "ACTUAL", "primaryCompletion": "2030-03-04", "completion": "2037-05-06", "lastUpdate": "2026-08-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "capitello-281", "name": "CAPItello-281", "nct": "NCT04493853", "corpus": { "status": "positive", "phase": "3", "enrolled": 1012, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04493853", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1012, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-07", "completion": "2027-03-31", "lastUpdate": "2026-09-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "capitello-291", "name": "CAPItello-291", "nct": "NCT04305496", "corpus": { "status": "positive", "phase": "3", "enrolled": 708, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients.", "yearReported": 2022 }, "registry": { "nct": "NCT04305496", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 818, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-05-09", "completion": "2026-06-22", "lastUpdate": "2026-04-30" }, "contradictions": [], "explained": [ "enrolment 708 in the corpus (randomised), 818 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients." ], "papers": [] }, { "id": "chaarted", "name": "CHAARTED (E3805)", "nct": "NCT00309985", "corpus": { "status": "positive", "phase": "3", "enrolled": 790, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00309985", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 790, "enrolmentType": "ACTUAL", "primaryCompletion": "2013-12-23", "completion": "2025-01-31", "lastUpdate": "2025-12-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "embark", "name": "EMBARK", "nct": "NCT02319837", "corpus": { "status": "positive", "phase": "3", "enrolled": 1068, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT02319837", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1068, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-01-31", "completion": "2026-09-19", "lastUpdate": "2026-07-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ember-3", "name": "EMBER-3", "nct": "NCT04975308", "corpus": { "status": "positive", "phase": "3", "enrolled": 874, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04975308", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 874, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-06-24", "completion": "2027-08", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "emerald", "name": "EMERALD", "nct": "NCT03778931", "corpus": { "status": "positive", "phase": "3", "enrolled": 478, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03778931", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 478, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-24", "completion": "2024-08-22", "lastUpdate": "2025-09-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "evera", "name": "evERA", "nct": "NCT05306340", "corpus": { "status": "positive", "phase": "3", "enrolled": 320, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication.", "yearReported": 2025 }, "registry": { "nct": "NCT05306340", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 373, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-16", "completion": "2026-10-15", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [ "enrolment 320 in the corpus (randomised), 373 on the registry (actual; 14 percent apart): ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication." ], "papers": [] }, { "id": "fourlight-1", "name": "FOURLIGHT-1", "nct": "NCT06105632", "corpus": { "status": "positive", "phase": "2", "enrolled": 333, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06105632", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 333, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-12", "completion": "2028-01-21", "lastUpdate": "2026-08-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "latitude", "name": "LATITUDE", "nct": "NCT01715285", "corpus": { "status": "positive", "phase": "3", "enrolled": 1209, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01715285", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1209, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-10-31", "completion": "2022-02-13", "lastUpdate": "2025-02-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "lidera", "name": "lidERA", "nct": "NCT04961996", "corpus": { "status": "positive", "phase": "3", "enrolled": 4170, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04961996", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 4170, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-08", "completion": "2033-09-30", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "magnitude", "name": "MAGNITUDE", "nct": "NCT03748641", "corpus": { "status": "mixed", "phase": "3", "enrolled": 423, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort.", "yearReported": 2022 }, "registry": { "nct": "NCT03748641", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 765, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-10-08", "completion": "2027-12-31", "lastUpdate": "2026-09-25" }, "contradictions": [], "explained": [ "enrolment 423 in the corpus (randomised), 765 on the registry (actual; 45 percent apart): ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort." ], "papers": [] }, { "id": "mevpro-1", "name": "MEVPRO-1", "nct": "NCT06551324", "corpus": { "status": "active", "phase": "3", "enrolled": 600, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06551324", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-12-28", "completion": "2028-10-29", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "monaleesa-2", "name": "MONALEESA-2", "nct": "NCT01958021", "corpus": { "status": "positive", "phase": "3", "enrolled": 668, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01958021", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 668, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-01-29", "completion": "2023-03-16", "lastUpdate": "2025-03-07" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "monarch-3", "name": "MONARCH 3", "nct": "NCT02246621", "corpus": { "status": "positive", "phase": "3", "enrolled": 493, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02246621", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 493, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-01-31", "completion": "2026-12", "lastUpdate": "2026-02-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "monarche", "name": "monarchE", "nct": "NCT03155997", "corpus": { "status": "positive", "phase": "3", "enrolled": 5637, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03155997", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5637, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-16", "completion": "2029-05", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "natalee", "name": "NATALEE", "nct": "NCT03701334", "corpus": { "status": "positive", "phase": "3", "enrolled": 5101, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03701334", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5101, "enrolmentType": "ACTUAL", "primaryCompletion": "2030-05-29", "completion": "2030-05-29", "lastUpdate": "2026-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "pallas-penelope-b", "name": "PALLAS & PENELOPE-B", "nct": "NCT02513394", "corpus": { "status": "negative", "phase": "3", "enrolled": 6862, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02513394", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5796, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-11", "completion": "2028-12", "lastUpdate": "2026-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "paloma-2", "name": "PALOMA-2", "nct": "NCT01740427", "corpus": { "status": "mixed", "phase": "3", "enrolled": 666, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01740427", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 666, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-02-26", "completion": "2023-11-09", "lastUpdate": "2024-11-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "peace-1", "name": "PEACE-1", "nct": "NCT01957436", "corpus": { "status": "positive", "phase": "3", "enrolled": 1173, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT01957436", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1173, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-18", "completion": "2032-12", "lastUpdate": "2024-11-12" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "persevera", "name": "persevERA", "nct": "NCT04546009", "corpus": { "status": "negative", "phase": "3", "enrolled": 992, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT04546009", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-30", "completion": "2027-07-31", "lastUpdate": "2026-08-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "postmonarch", "name": "postMONARCH", "nct": "NCT05169567", "corpus": { "status": "positive", "phase": "3", "enrolled": 368, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05169567", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 368, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-02-08", "completion": "2027-12", "lastUpdate": "2026-01-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "propel", "name": "PROpel", "nct": "NCT03732820", "corpus": { "status": "positive", "phase": "3", "enrolled": 796, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03732820", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 895, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-07-30", "completion": "2027-02-05", "lastUpdate": "2026-08-18" }, "contradictions": [], "explained": [ "enrolment 796 in the corpus (randomised), 895 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis." ], "papers": [] }, { "id": "psmafore", "name": "PSMAfore", "nct": "NCT04689828", "corpus": { "status": "positive", "phase": "3", "enrolled": 469, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04689828", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 469, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-10-02", "completion": "2026-09-10", "lastUpdate": "2026-09-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-09-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "soft-text", "name": "SOFT & TEXT", "nct": "NCT00066690", "corpus": { "status": "positive", "phase": "3", "enrolled": 5738, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": { "nct": "NCT00066690", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 3066, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-05", "completion": "2024-11-06", "lastUpdate": "2026-08-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "solar-1", "name": "SOLAR-1", "nct": "NCT02437318", "corpus": { "status": "positive", "phase": "3", "enrolled": 572, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT02437318", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 572, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-06-12", "completion": "2023-06-09", "lastUpdate": "2025-02-13" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42775824", "doi": "10.2340/1651-226x.2026.46486", "title": "Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.", "journal": "Acta Oncol", "date": "2026-09-23" } ] }, { "id": "stampede", "name": "STAMPEDE", "nct": "NCT00268476", "corpus": { "status": "positive", "phase": "platform", "enrolled": 11992, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00268476", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-03", "completion": "2030-12", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "talapro-2", "name": "TALAPRO-2", "nct": "NCT03395197", "corpus": { "status": "positive", "phase": "3", "enrolled": 805, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo).", "yearReported": 2023 }, "registry": { "nct": "NCT03395197", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1054, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-10-03", "completion": "2027-06-30", "lastUpdate": "2026-09-29" }, "contradictions": [], "explained": [ "enrolment 805 in the corpus (randomised), 1054 on the registry (actual; 24 percent apart): ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo)." ], "papers": [] }, { "id": "veritac-2", "name": "VERITAC-2", "nct": "NCT05654623", "corpus": { "status": "mixed", "phase": "3", "enrolled": 624, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05654623", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 624, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-31", "completion": "2028-05-15", "lastUpdate": "2026-03-18" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "capitello-291", "name": "CAPItello-291", "text": "enrolment 708 in the corpus (randomised), 818 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients." }, { "ref": "evera", "name": "evERA", "text": "enrolment 320 in the corpus (randomised), 373 on the registry (actual; 14 percent apart): ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication." }, { "ref": "magnitude", "name": "MAGNITUDE", "text": "enrolment 423 in the corpus (randomised), 765 on the registry (actual; 45 percent apart): ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort." }, { "ref": "propel", "name": "PROpel", "text": "enrolment 796 in the corpus (randomised), 895 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis." }, { "ref": "talapro-2", "name": "TALAPRO-2", "text": "enrolment 805 in the corpus (randomised), 1054 on the registry (actual; 24 percent apart): ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo)." } ] }, { "id": "immunotherapy-roadmap", "name": "Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 4, "checked": 4, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-067", "name": "CheckMate 067", "nct": "NCT01844505", "corpus": { "status": "positive", "phase": "3", "enrolled": 945, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT01844505", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 945, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-08-01", "completion": "2024-04-19", "lastUpdate": "2025-05-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interpath-001", "name": "INTerpath-001 (V940-001)", "nct": "NCT05933577", "corpus": { "status": "positive", "phase": "3", "enrolled": 1137, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT05933577", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1089, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-10-26", "completion": "2030-09-26", "lastUpdate": "2025-09-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "kras-roadmap", "name": "KRAS roadmap: undruggable → G12C → pan-RAS", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "lung-cancer-evidence-roadmap", "name": "Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch", "asOf": "2026-09-25", "since": "2026-09-25", "counts": { "trials": 7, "checked": 7, "contradictions": 0, "explained": 0, "papers": 0, "watch": 10, "watchPassed": 0 }, "trials": [ { "id": "adriatic", "name": "ADRIATIC", "nct": "NCT03703297", "corpus": { "status": "positive", "phase": "3", "enrolled": 730, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03703297", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 730, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-15", "completion": "2026-10-23", "lastUpdate": "2025-11-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "alina", "name": "ALINA", "nct": "NCT03456076", "corpus": { "status": "positive", "phase": "3", "enrolled": 257, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03456076", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 257, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-06-26", "completion": "2031-11-19", "lastUpdate": "2026-07-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "crown", "name": "CROWN", "nct": "NCT03052608", "corpus": { "status": "positive", "phase": "3", "enrolled": 296, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03052608", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 296, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-20", "completion": "2028-12-31", "lastUpdate": "2025-11-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dellphi-304", "name": "DeLLphi-304", "nct": "NCT05740566", "corpus": { "status": "positive", "phase": "3", "enrolled": 509, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05740566", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 509, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-29", "completion": "2028-03-26", "lastUpdate": "2026-01-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "flaura2", "name": "FLAURA2", "nct": "NCT04035486", "corpus": { "status": "positive", "phase": "3", "enrolled": 587, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04035486", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 587, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-04-03", "completion": "2027-09-30", "lastUpdate": "2026-09-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "laura", "name": "LAURA", "nct": "NCT03521154", "corpus": { "status": "positive", "phase": "3", "enrolled": 216, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03521154", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 216, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-05", "completion": "2027-10-29", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mariposa", "name": "MARIPOSA", "nct": "NCT04487080", "corpus": { "status": "positive", "phase": "3", "enrolled": 1074, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04487080", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1074, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-11", "completion": "2028-02-16", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "ADRIATIC: final analysis of durvalumab, and the unblinding of the durvalumab plus tremelimumab arm, in limited-stage small-cell lung cancer", "expected": "Study completion 23 October 2026 (estimated, ClinicalTrials.gov NCT03703297)", "source": "https://clinicaltrials.gov/study/NCT03703297", "refs": [ "paper-adriatic-nejm-2024", "adriatic" ], "passed": false, "contradictions": [] }, { "item": "IMpower010: final overall survival for adjuvant atezolizumab after chemotherapy in resected disease", "expected": "Study completion 31 August 2027 (estimated, ClinicalTrials.gov NCT02486718)", "source": "https://clinicaltrials.gov/study/NCT02486718", "refs": [ "paper-felip-impower010-adjuvant-atezolizumab-lancet-2021" ], "passed": false, "contradictions": [] }, { "item": "FLAURA2: overall survival for osimertinib with chemotherapy against osimertinib alone", "expected": "Study completion 30 September 2027 (estimated, ClinicalTrials.gov NCT04035486)", "source": "https://clinicaltrials.gov/study/NCT04035486", "refs": [ "paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023", "flaura2" ], "passed": false, "contradictions": [] }, { "item": "LAURA: overall survival for osimertinib after chemoradiotherapy in stage III EGFR-mutated disease", "expected": "Study completion 29 October 2027 (estimated, ClinicalTrials.gov NCT03521154)", "source": "https://clinicaltrials.gov/study/NCT03521154", "refs": [ "paper-lu-laura-osimertinib-stage-iii-nejm-2024", "laura" ], "passed": false, "contradictions": [] }, { "item": "MARIPOSA: final overall survival for amivantamab plus lazertinib against osimertinib in first line", "expected": "Study completion 16 February 2028 (estimated, ClinicalTrials.gov NCT04487080)", "source": "https://clinicaltrials.gov/study/NCT04487080", "refs": [ "paper-mariposa-nejm-2024", "mariposa" ], "passed": false, "contradictions": [] }, { "item": "DeLLphi-304: final analysis of tarlatamab against chemotherapy in relapsed small-cell lung cancer", "expected": "Study completion 26 March 2028 (estimated, ClinicalTrials.gov NCT05740566)", "source": "https://clinicaltrials.gov/study/NCT05740566", "refs": [ "paper-tarlatamab-sclc-n-engl-j-med-2025", "paper-dellphi-301-nejm-2023", "dellphi-304" ], "passed": false, "contradictions": [] }, { "item": "AEGEAN: final overall survival for perioperative durvalumab in resectable disease", "expected": "Study completion 11 September 2028 (estimated, ClinicalTrials.gov NCT03800134)", "source": "https://clinicaltrials.gov/study/NCT03800134", "refs": [ "paper-heymach-aegean-perioperative-durvalumab-nejm-2023" ], "passed": false, "contradictions": [] }, { "item": "CROWN: final analysis of first-line lorlatinib against crizotinib, including long-term intracranial control", "expected": "Study completion 31 December 2028 (estimated, ClinicalTrials.gov NCT03052608)", "source": "https://clinicaltrials.gov/study/NCT03052608", "refs": [ "paper-shaw-crown-lorlatinib-crizotinib-nejm-2020", "crown" ], "passed": false, "contradictions": [] }, { "item": "ALINA: overall survival for adjuvant alectinib against chemotherapy in resected ALK-positive disease, the longest-dated of the practice-changing perioperative trials", "expected": "Study completion 19 November 2031 (estimated, ClinicalTrials.gov NCT03456076)", "source": "https://clinicaltrials.gov/study/NCT03456076", "refs": [ "paper-wu-alina-adjuvant-alectinib-nejm-2024", "alina" ], "passed": false, "contradictions": [] }, { "item": "TRACERx: the full evolutionary and ctDNA dataset on 814 patients, the deepest longitudinal study of lung cancer evolution", "expected": "Study completion November 2035 (estimated, ClinicalTrials.gov NCT01888601)", "source": "https://clinicaltrials.gov/study/NCT01888601", "refs": [ "paper-tracerx-100-nejm-2017", "paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017" ], "passed": false, "contradictions": [] } ], "contradictions": [], "explained": [] }, { "id": "molecular-imaging-roadmap", "name": "Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "paediatric-oncology-roadmap", "name": "Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 20, "checked": 20, "contradictions": 0, "explained": 6, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "action-dmg", "name": "ACTION", "nct": "NCT05580562", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 510, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05580562", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 510, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-06", "completion": "2028-06", "lastUpdate": "2026-04-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ccss", "name": "Childhood Cancer Survivor Study (CCSS)", "nct": "NCT01120353", "corpus": { "status": "active", "phase": "observational", "enrolled": 50000, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01120353", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 50000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-11", "completion": "2026-11", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "aall1731", "name": "COG AALL1731", "nct": "NCT03914625", "corpus": { "status": "positive", "phase": "3", "enrolled": 1440, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists an estimated 6,720 participants for the whole trial, which enrols all standard-risk patients; the NEJM 2024 interim analysis covered the 1,440 patients randomised (722 chemotherapy, 718 blinatumomab) before randomisation was stopped.", "yearReported": 2024 }, "registry": { "nct": "NCT03914625", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 6720, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-09-30", "completion": "2027-09-30", "lastUpdate": "2026-07-30" }, "contradictions": [], "explained": [ "enrolment 1440 in the corpus (randomised), 6720 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 6,720 participants for the whole trial, which enrols all standard-risk patients; the NEJM 2024 interim analysis covered the 1,440 patients randomised (722 chemotherapy, 718 blinatumomab) before randomisation was stopped." ], "papers": [] }, { "id": "aaml0531", "name": "COG AAML0531", "nct": "NCT00372593", "corpus": { "status": "positive", "phase": "3", "enrolled": 1070, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": { "nct": "NCT00372593", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1070, "enrolmentType": "ACTUAL", "primaryCompletion": "2013-08", "completion": "2020-09-30", "lastUpdate": "2021-03-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "acns0331", "name": "COG ACNS0331", "nct": "NCT00085735", "corpus": { "status": "mixed", "phase": "3", "enrolled": 549, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT00085735", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 549, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-03-31", "completion": "2024-12-31", "lastUpdate": "2026-06-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "anbl0032", "name": "COG ANBL0032", "nct": "NCT00026312", "corpus": { "status": "positive", "phase": "3", "enrolled": 226, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 1,449 participants (actual) enrolled over the life of the study; the NEJM 2010 analysis randomised 226 eligible patients.", "yearReported": 2010 }, "registry": { "nct": "NCT00026312", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1449, "enrolmentType": "ACTUAL", "primaryCompletion": "2012-01-12", "completion": "2025-12-31", "lastUpdate": "2026-03-05" }, "contradictions": [], "explained": [ "enrolment 226 in the corpus (randomised), 1449 on the registry (actual; 84 percent apart): ClinicalTrials.gov lists 1,449 participants (actual) enrolled over the life of the study; the NEJM 2010 analysis randomised 226 eligible patients." ], "papers": [] }, { "id": "anbl0532", "name": "COG ANBL0532", "nct": "NCT00567567", "corpus": { "status": "positive", "phase": "3", "enrolled": 665, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00567567", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 665, "enrolmentType": "ACTUAL", "primaryCompletion": "2015-02-27", "completion": "2022-03-31", "lastUpdate": "2022-04-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "anbl1531", "name": "COG ANBL1531", "nct": "NCT03126916", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT03126916", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 750, "enrolmentType": "ESTIMATED", "primaryCompletion": "2030-09-30", "completion": "2030-09-30", "lastUpdate": "2026-08-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "aren0533", "name": "COG AREN0533", "nct": "NCT00379340", "corpus": { "status": "positive", "phase": "3", "enrolled": 395, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00379340", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 395, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-06-30", "completion": "2026-03-31", "lastUpdate": "2026-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "eliana", "name": "ELIANA", "nct": "NCT02435849", "corpus": { "status": "positive", "phase": "2", "enrolled": 79, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists 80 participants (actual); the JCO 2023 three-year update reports 79 infused patients and the NEJM 2018 primary analysis 75.", "yearReported": 2018 }, "registry": { "nct": "NCT02435849", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 80, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-01-21", "completion": "2022-11-17", "lastUpdate": "2024-02-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "euramos-1", "name": "EURAMOS-1", "nct": "NCT00134030", "corpus": { "status": "negative", "phase": "3", "enrolled": 2260, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists 1,334 participants (actual), the patients randomised (618 poor responders and 716 good responders); the Lancet Oncology 2016 paper reports 2,260 patients registered from 325 sites in 17 countries.", "yearReported": 2016 }, "registry": { "nct": "NCT00134030", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1334, "enrolmentType": "ACTUAL", "primaryCompletion": "2015-01-31", "completion": "2022-09-30", "lastUpdate": "2023-06-07" }, "contradictions": [], "explained": [ "enrolment 2260 in the corpus (registered), 1334 on the registry (actual; 69 percent apart): ClinicalTrials.gov lists 1,334 participants (actual), the patients randomised (618 poor responders and 716 good responders); the Lancet Oncology 2016 paper reports 2,260 patients registered from 325 sites in 17 countries." ], "papers": [] }, { "id": "firefly-1", "name": "FIREFLY-1", "nct": "NCT04775485", "corpus": { "status": "positive", "phase": "2", "enrolled": 141, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04775485", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 141, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-05-31", "completion": "2027-05-31", "lastUpdate": "2025-04-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "gd2-cart01", "name": "GD2-CART01 (Bambino Gesù phase 1/2)", "nct": "NCT03373097", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 27, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists an estimated 42 participants for the phase 1/2 study, which is still active; the NEJM 2023 paper reports the 27 patients treated.", "yearReported": 2023 }, "registry": { "nct": "NCT03373097", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 42, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-12", "completion": "2027-12", "lastUpdate": "2026-09-30" }, "contradictions": [], "explained": [ "enrolment 27 in the corpus (treated), 42 on the registry (estimated; 36 percent apart): ClinicalTrials.gov lists an estimated 42 participants for the phase 1/2 study, which is still active; the NEJM 2023 paper reports the 27 patients treated." ], "papers": [] }, { "id": "int-0091", "name": "INT-0091 (Ewing sarcoma)", "nct": "NCT00002516", "corpus": { "status": "positive", "phase": "3", "enrolled": 518, "enrolledBasis": "registry", "yearReported": 2003 }, "registry": { "nct": "NCT00002516", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "lastUpdate": "2013-09-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "inter-b-nhl-ritux-2010", "name": "Inter-B-NHL Ritux 2010", "nct": "NCT01516580", "corpus": { "status": "positive", "phase": "3", "enrolled": 482, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01516580", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 482, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-06-13", "completion": "2022-11-16", "lastUpdate": "2026-02-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interfant-06", "name": "Interfant-06", "nct": "NCT00550992", "corpus": { "status": "mixed", "phase": "3", "enrolled": 651, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 445 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the JCO 2019 paper reports 651 infants included.", "yearReported": 2019 }, "registry": { "nct": "NCT00550992", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 445, "enrolmentType": "ESTIMATED", "primaryCompletion": "2020-12", "lastUpdate": "2019-07-30" }, "contradictions": [], "explained": [ "enrolment 651 in the corpus (registered), 445 on the registry (estimated; 46 percent apart): ClinicalTrials.gov lists an estimated 445 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the JCO 2019 paper reports 651 infants included." ], "papers": [] }, { "id": "pediatric-match", "name": "NCI-COG Pediatric MATCH (APEC1621)", "nct": "NCT03155620", "corpus": { "status": "active", "phase": "platform", "enrolled": 1377, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03155620", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 1377, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-31", "completion": "2027-01-06", "lastUpdate": "2026-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "hr-nbl1", "name": "SIOPEN HR-NBL1", "nct": "NCT01704716", "corpus": { "status": "mixed", "phase": "3", "enrolled": 3300, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01704716", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 3300, "enrolmentType": "ESTIMATED", "primaryCompletion": "2021-09-30", "completion": "2026-09", "lastUpdate": "2020-10-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tadpole", "name": "TADPOLE (CDRB436G2201)", "nct": "NCT02684058", "corpus": { "status": "positive", "phase": "2", "enrolled": 110, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 151 participants (actual) across the study's cohorts; the NEJM 2023 low-grade glioma analysis randomised 110 patients (73 dabrafenib plus trametinib, 37 chemotherapy).", "yearReported": 2023 }, "registry": { "nct": "NCT02684058", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 151, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-23", "completion": "2023-04-28", "lastUpdate": "2023-12-13" }, "contradictions": [], "explained": [ "enrolment 110 in the corpus (randomised), 151 on the registry (actual; 27 percent apart): ClinicalTrials.gov lists 151 participants (actual) across the study's cohorts; the NEJM 2023 low-grade glioma analysis randomised 110 patients (73 dabrafenib plus trametinib, 37 chemotherapy)." ], "papers": [] }, { "id": "tower", "name": "TOWER", "nct": "NCT02013167", "corpus": { "status": "positive", "phase": "3", "enrolled": 405, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02013167", "status": "TERMINATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 405, "enrolmentType": "ACTUAL", "primaryCompletion": "2015-12-29", "completion": "2017-03-14", "lastUpdate": "2024-03-05" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "aall1731", "name": "COG AALL1731", "text": "enrolment 1440 in the corpus (randomised), 6720 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 6,720 participants for the whole trial, which enrols all standard-risk patients; the NEJM 2024 interim analysis covered the 1,440 patients randomised (722 chemotherapy, 718 blinatumomab) before randomisation was stopped." }, { "ref": "anbl0032", "name": "COG ANBL0032", "text": "enrolment 226 in the corpus (randomised), 1449 on the registry (actual; 84 percent apart): ClinicalTrials.gov lists 1,449 participants (actual) enrolled over the life of the study; the NEJM 2010 analysis randomised 226 eligible patients." }, { "ref": "euramos-1", "name": "EURAMOS-1", "text": "enrolment 2260 in the corpus (registered), 1334 on the registry (actual; 69 percent apart): ClinicalTrials.gov lists 1,334 participants (actual), the patients randomised (618 poor responders and 716 good responders); the Lancet Oncology 2016 paper reports 2,260 patients registered from 325 sites in 17 countries." }, { "ref": "gd2-cart01", "name": "GD2-CART01 (Bambino Gesù phase 1/2)", "text": "enrolment 27 in the corpus (treated), 42 on the registry (estimated; 36 percent apart): ClinicalTrials.gov lists an estimated 42 participants for the phase 1/2 study, which is still active; the NEJM 2023 paper reports the 27 patients treated." }, { "ref": "interfant-06", "name": "Interfant-06", "text": "enrolment 651 in the corpus (registered), 445 on the registry (estimated; 46 percent apart): ClinicalTrials.gov lists an estimated 445 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the JCO 2019 paper reports 651 infants included." }, { "ref": "tadpole", "name": "TADPOLE (CDRB436G2201)", "text": "enrolment 110 in the corpus (randomised), 151 on the registry (actual; 27 percent apart): ClinicalTrials.gov lists 151 participants (actual) across the study's cohorts; the NEJM 2023 low-grade glioma analysis randomised 110 patients (73 dabrafenib plus trametinib, 37 chemotherapy)." } ] }, { "id": "pancreatic-roadmap", "name": "Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question", "asOf": "2026-09-24", "since": "2026-09-24", "counts": { "trials": 18, "checked": 14, "contradictions": 1, "explained": 1, "papers": 0, "watch": 11, "watchPassed": 1 }, "trials": [ { "id": "nct05968326", "name": "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC", "nct": "NCT05968326", "corpus": { "status": "active", "phase": "2", "enrolled": 260, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05968326", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 260, "enrolmentType": "ESTIMATED", "primaryCompletion": "2031-01-01", "completion": "2031-01-01", "lastUpdate": "2026-09-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct07522073", "name": "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma", "nct": "NCT07522073", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 588, "enrolledBasis": "registry" }, "registry": { "nct": "NCT07522073", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 588, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-09-15", "completion": "2029-03-19", "lastUpdate": "2026-09-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "amplify-7p", "name": "AMPLIFY-7P", "nct": "NCT05726864", "corpus": { "status": "negative", "phase": "1/2", "enrolled": 158, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT05726864", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 158, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-04-20", "completion": "2026-11", "lastUpdate": "2026-07-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "conko-001", "name": "CONKO-001", "nct": "ISRCTN34802808", "corpus": { "status": "positive", "phase": "3", "enrolled": 368, "enrolledBasis": "randomised", "enrolledNote": "CONKO-001 has no ClinicalTrials.gov record; the figure is the 368 randomised in the JAMA report (354 in the intention-to-treat analysis); the trial is registered as ISRCTN34802808.", "yearReported": 2013 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "espac-4", "name": "ESPAC-4", "nct": "ISRCTN96397434", "corpus": { "status": "positive", "phase": "3", "enrolled": 732, "enrolledBasis": "registered", "enrolledNote": "ESPAC-4 has no ClinicalTrials.gov record; the figure is the 732 enrolled in the Lancet report, of whom 730 were analysed (366 gemcitabine, 364 gemcitabine plus capecitabine); the trial is registered as ISRCTN96397434.", "yearReported": 2017 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "espac-5", "name": "ESPAC-5", "nct": "ISRCTN89500674", "corpus": { "status": "positive", "phase": "2", "enrolled": 90, "enrolledBasis": "randomised", "enrolledNote": "ESPAC-5 has no ClinicalTrials.gov record and the Lancet Gastroenterology and Hepatology report does not print a registry id; the figure is the 90 patients randomised between 2014 and 2018 (86 analysed).", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "lap07", "name": "LAP07", "nct": "NCT00634725", "corpus": { "status": "negative", "phase": "3", "enrolled": 449, "enrolledBasis": "registered", "enrolledNote": "The registry gives an estimated 820; the JAMA report enrolled 449 patients, 442 of whom had the first randomisation and 269 the second.", "yearReported": 2016 }, "registry": { "nct": "NCT00634725", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 820, "enrolmentType": "ESTIMATED", "primaryCompletion": "2013-02", "completion": "2014-09", "lastUpdate": "2015-12-11" }, "contradictions": [], "explained": [ "enrolment 449 in the corpus (registered), 820 on the registry (estimated; 45 percent apart): The registry gives an estimated 820; the JAMA report enrolled 449 patients, 442 of whom had the first randomisation and 269 the second." ], "papers": [] }, { "id": "napoli-3", "name": "NAPOLI 3", "nct": "NCT04083235", "corpus": { "status": "positive", "phase": "3", "enrolled": 770, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04083235", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 770, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-07-23", "completion": "2025-02-18", "lastUpdate": "2026-04-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "panova-3", "name": "PANOVA-3", "nct": "NCT03377491", "corpus": { "status": "positive", "phase": "3", "enrolled": 571, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT03377491", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 571, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-16", "completion": "2024-10-16", "lastUpdate": "2026-01-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct07262567", "name": "Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer", "nct": "NCT07262567", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 320, "enrolledBasis": "registry" }, "registry": { "nct": "NCT07262567", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 320, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-06", "completion": "2028-06", "lastUpdate": "2026-08-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "polo", "name": "POLO", "nct": "NCT02184195", "corpus": { "status": "mixed", "phase": "3", "enrolled": 154, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT02184195", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 154, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-01-15", "completion": "2023-01-27", "lastUpdate": "2023-09-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "precede", "name": "PRECEDE", "nct": "NCT04970056", "corpus": { "status": "recruiting", "phase": "observational", "enrolled": 20000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04970056", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 20000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2030-12-31", "completion": "2030-12-31", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "preopanc", "name": "PREOPANC-1", "nct": "NTR3709", "corpus": { "status": "mixed", "phase": "3", "enrolled": 246, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "prodige-24", "name": "PRODIGE 24 / CCTG PA6", "nct": "NCT01526135", "corpus": { "status": "positive", "phase": "3", "enrolled": 493, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01526135", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 493, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03", "completion": "2021-07-16", "lastUpdate": "2022-01-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rasolute-302", "name": "RASolute 302", "nct": "NCT06625320", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06625320", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06", "completion": "2027-12", "lastUpdate": "2026-06-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct07252232", "name": "Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)", "nct": "NCT07252232", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 500, "enrolledBasis": "registry" }, "registry": { "nct": "NCT07252232", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-05-10", "completion": "2030-07-10", "lastUpdate": "2026-09-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct07491445", "name": "Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma", "nct": "NCT07491445", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 900, "enrolledBasis": "registry" }, "registry": { "nct": "NCT07491445", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 900, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-06", "completion": "2029-03", "lastUpdate": "2026-09-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct07805954", "name": "Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut", "nct": "NCT07805954", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 400, "enrolledBasis": "registry" }, "registry": { "nct": "NCT07805954", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 400, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-03", "completion": "2030-04", "lastUpdate": "2026-09-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "RASolute 302 primary completion on the registry (daraxonrasib versus chemotherapy, previously treated metastatic disease, 500 participants, actual; published and approved 2026)", "expected": "2026-06", "source": "https://clinicaltrials.gov/study/NCT06625320", "refs": [ "rasolute-302", "daraxonrasib", "paper-daraxonrasib-pancreatic-n-engl-j-med-2026" ], "passed": true, "contradictions": [] }, { "item": "AMPLIFY-7P study completion (ELI-002 7P adjuvant KRAS vaccine, 158 participants; primary completion 20 April 2026, actual)", "expected": "2026-11", "source": "https://clinicaltrials.gov/study/NCT05726864", "refs": [ "amplify-7p", "eli-002-7p", "shared-antigen-vaccine" ], "passed": false, "contradictions": [] }, { "item": "PREOPANC-3 primary completion: perioperative versus adjuvant modified FOLFIRINOX for resectable pancreatic cancer (378 estimated participants; active, not recruiting)", "expected": "2027-01", "source": "https://clinicaltrials.gov/study/NCT04927780", "refs": [ "preopanc", "folfirinox", "neoadjuvant-adjuvant", "idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease" ], "passed": false, "contradictions": [] }, { "item": "RASolute 302 study completion on the registry", "expected": "2027-12", "source": "https://clinicaltrials.gov/study/NCT06625320", "refs": [ "rasolute-302", "daraxonrasib" ], "passed": false, "contradictions": [] }, { "item": "RASolute 303 primary completion: daraxonrasib alone or with gemcitabine and nab-paclitaxel versus chemotherapy, first line metastatic (900 estimated participants; recruiting)", "expected": "2028-06", "source": "https://clinicaltrials.gov/study/NCT07491445", "refs": [ "nct07491445", "daraxonrasib", "gemcitabine-nab-paclitaxel", "idea-pdac-ras-inhibitor-combinations-and-sequencing" ], "passed": false, "contradictions": [] }, { "item": "DAWN-303 primary completion: chemotherapy with or without INCB161734 in untreated KRAS G12D metastatic disease (588 estimated participants; recruiting)", "expected": "2028-09-15", "source": "https://clinicaltrials.gov/study/NCT07522073", "refs": [ "nct07522073", "kras-inhibitors", "idea-pdac-ras-inhibitor-combinations-and-sequencing" ], "passed": false, "contradictions": [] }, { "item": "Alliance A021806 primary completion: perioperative versus adjuvant modified FOLFIRINOX for resectable pancreatic cancer (358 participants, actual; active, not recruiting)", "expected": "2028-12-31", "source": "https://clinicaltrials.gov/study/NCT04340141", "refs": [ "folfirinox", "neoadjuvant-adjuvant", "idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease" ], "passed": false, "contradictions": [] }, { "item": "RASolute 309 primary completion: zoldonrasib plus daraxonrasib versus gemcitabine and nab-paclitaxel, first line KRAS G12D metastatic disease (400 estimated participants; recruiting)", "expected": "2029-03", "source": "https://clinicaltrials.gov/study/NCT07805954", "refs": [ "nct07805954", "zoldonrasib", "daraxonrasib", "g12d-plus-pan-ras", "idea-pdac-ras-inhibitor-combinations-and-sequencing" ], "passed": false, "contradictions": [] }, { "item": "RASolute 304 primary completion: adjuvant daraxonrasib in resected pancreatic ductal adenocarcinoma (500 estimated participants; recruiting)", "expected": "2029-05-10", "source": "https://clinicaltrials.gov/study/NCT07252232", "refs": [ "nct07252232", "daraxonrasib", "prodige-24" ], "passed": false, "contradictions": [ "PRODIGE 24 / CCTG PA6: watch item expects 2029-05-10; the registry now lists primary completion 2018-03 and completion 2021-07-16" ] }, { "item": "PRECEDE (Pancreatic Cancer Early Detection Consortium) primary completion: 20,000 estimated high-risk participants under surveillance (recruiting)", "expected": "2030-12-31", "source": "https://clinicaltrials.gov/study/NCT04970056", "refs": [ "precede", "pancreatic-surveillance", "idea-pdac-surveillance-for-every-germline-carrier" ], "passed": false, "contradictions": [] }, { "item": "IMCODE003 primary completion: adjuvant autogene cevumeran plus atezolizumab and modified FOLFIRINOX versus modified FOLFIRINOX alone after resection (260 estimated participants; phase 2; active, not recruiting)", "expected": "2031-01-01", "source": "https://clinicaltrials.gov/study/NCT05968326", "refs": [ "nct05968326", "autogene-cevumeran", "neoantigen-mrna-vaccine", "paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025" ], "passed": false, "contradictions": [] } ], "contradictions": [ { "ref": "nct07252232", "name": "RASolute 304 primary completion: adjuvant daraxonrasib in resected pancreatic ductal adenocarcinoma (500 estimated participants; recruiting)", "text": "PRODIGE 24 / CCTG PA6: watch item expects 2029-05-10; the registry now lists primary completion 2018-03 and completion 2021-07-16" } ], "explained": [ { "ref": "lap07", "name": "LAP07", "text": "enrolment 449 in the corpus (registered), 820 on the registry (estimated; 45 percent apart): The registry gives an estimated 820; the JAMA report enrolled 449 patients, 442 of whom had the first randomisation and 269 the second." } ] }, { "id": "cure-paths", "name": "Paths to cures: interception, eradication, control", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "prostate-roadmap", "name": "Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch", "asOf": "2026-09-25", "since": "2026-09-25", "counts": { "trials": 6, "checked": 6, "contradictions": 0, "explained": 0, "papers": 0, "watch": 8, "watchPassed": 0 }, "trials": [ { "id": "nct03767244", "name": "A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy", "nct": "NCT03767244", "corpus": { "status": "active", "phase": "3", "enrolled": 2517, "enrolledBasis": "registry" }, "registry": { "nct": "NCT03767244", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2517, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-12-01", "completion": "2028-10-13", "lastUpdate": "2026-09-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct05939414", "name": "An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.", "nct": "NCT05939414", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 450, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05939414", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 450, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-04-25", "completion": "2031-10-03", "lastUpdate": "2026-09-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "capitello-281", "name": "CAPItello-281", "nct": "NCT04493853", "corpus": { "status": "positive", "phase": "3", "enrolled": 1012, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04493853", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1012, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-07", "completion": "2027-03-31", "lastUpdate": "2026-09-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "psmaddition", "name": "PSMAddition", "nct": "NCT04720157", "corpus": { "status": "positive", "phase": "3", "enrolled": 1144, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04720157", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1140, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-13", "completion": "2027-02-11", "lastUpdate": "2026-06-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "stampede", "name": "STAMPEDE", "nct": "NCT00268476", "corpus": { "status": "positive", "phase": "platform", "enrolled": 11992, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00268476", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-03", "completion": "2030-12", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct04821622", "name": "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC", "nct": "NCT04821622", "corpus": { "status": "active", "phase": "3", "enrolled": 599, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04821622", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 599, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02-18", "completion": "2027-08-28", "lastUpdate": "2026-09-04" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "ProBio: the biomarker-driven outcome-adaptive platform in metastatic prostate cancer, the first trial designed to compare treatment strategies rather than single drugs in this disease", "expected": "Primary completion and study completion December 2026 (estimated, ClinicalTrials.gov NCT03903835)", "source": "https://clinicaltrials.gov/study/NCT03903835", "refs": [ "idea-prostate-randomise-the-sequence-not-only-the-drugs" ], "passed": false, "contradictions": [] }, { "item": "PSMAddition: lutetium-177 PSMA-617 added to standard care in metastatic hormone-sensitive disease, the earliest setting radioligand therapy has been tested in", "expected": "Study completion 11 February 2027 (estimated; primary completion 13 January 2025 actual, ClinicalTrials.gov NCT04720157)", "source": "https://clinicaltrials.gov/study/NCT04720157", "refs": [ "paper-psmaddition-lancet-2026", "psmaddition" ], "passed": false, "contradictions": [] }, { "item": "CAPItello-281: capivasertib with abiraterone in PTEN-deficient metastatic hormone-sensitive disease, the first PI3K-pathway result in a biomarker-selected prostate population", "expected": "Study completion 31 March 2027 (estimated; primary completion 7 October 2024 actual, ClinicalTrials.gov NCT04493853)", "source": "https://clinicaltrials.gov/study/NCT04493853", "refs": [ "paper-capitello-281-ann-oncol-2026", "capitello-281", "paper-tcga-molecular-taxonomy-primary-prostate-cell-2015" ], "passed": false, "contradictions": [] }, { "item": "TALAPRO-3: talazoparib with enzalutamide in DNA damage repair gene-mutated metastatic hormone-sensitive disease, the PARP combination moved to the hormone-sensitive setting", "expected": "Study completion 28 August 2027 (estimated; primary completion 18 February 2026 actual, ClinicalTrials.gov NCT04821622)", "source": "https://clinicaltrials.gov/study/NCT04821622", "refs": [ "paper-nct04821622-n-engl-j-med-2026", "nct04821622", "idea-prostate-hrr-testing-at-metastatic-diagnosis" ], "passed": false, "contradictions": [] }, { "item": "PROTEUS: perioperative apalutamide with androgen deprivation around radical prostatectomy in high-risk localised disease, the largest test of intensification before the operation", "expected": "Primary completion 1 December 2026 and study completion 13 October 2028 (both estimated, ClinicalTrials.gov NCT03767244)", "source": "https://clinicaltrials.gov/study/NCT03767244", "refs": [ "paper-nct03767244-n-engl-j-med-2026", "nct03767244" ], "passed": false, "contradictions": [] }, { "item": "PEACE III: radium-223 with enzalutamide against enzalutamide alone in bone-metastatic castration-resistant disease, and the bone-protecting agent question it raised", "expected": "Study completion December 2028 (estimated; primary completion 19 February 2024 actual, ClinicalTrials.gov NCT02194842)", "source": "https://clinicaltrials.gov/study/NCT02194842", "refs": [ "paper-alsympca-radium-223-nejm-2013", "paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025" ], "passed": false, "contradictions": [] }, { "item": "PSMA-DC: lutetium-177 vipivotide tetraxetan against observation in oligometastatic castration-sensitive disease detected on PSMA imaging, the test of whether a systemic radioligand can replace metastasis-directed treatment", "expected": "Primary completion 25 April 2028 and study completion 3 October 2031 (both estimated, ClinicalTrials.gov NCT05939414)", "source": "https://clinicaltrials.gov/study/NCT05939414", "refs": [ "nct05939414", "paper-phillips-jama-oncol", "idea-psma-pet-guided-mdt" ], "passed": false, "contradictions": [] }, { "item": "STAMPEDE2: the successor platform, testing stereotactic radiotherapy to metastases, lutetium-177 PSMA-617 and niraparib with abiraterone against contemporary standard care, with 3,360 men planned", "expected": "Primary completion April 2031 and study completion March 2032 (both estimated, ClinicalTrials.gov NCT06320067)", "source": "https://clinicaltrials.gov/study/NCT06320067", "refs": [ "stampede", "paper-stampede-abiraterone-high-risk-attard-lancet-2022", "idea-prostate-randomise-the-sequence-not-only-the-drugs" ], "passed": false, "contradictions": [] } ], "contradictions": [], "explained": [] }, { "id": "frontier-2035", "name": "Radical oncology: what could change the war by 2035", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "radiopharma-roadmap", "name": "Radiopharmaceutical roadmap: iodine → lutetium → actinium", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 2, "checked": 2, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "psmafore", "name": "PSMAfore", "nct": "NCT04689828", "corpus": { "status": "positive", "phase": "3", "enrolled": 469, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04689828", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 469, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-10-02", "completion": "2026-09-10", "lastUpdate": "2026-09-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "vision", "name": "VISION", "nct": "NCT03511664", "corpus": { "status": "positive", "phase": "3", "enrolled": 861, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03511664", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 861, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-01-27", "completion": "2023-12-14", "lastUpdate": "2025-01-13" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "radiation-roadmap", "name": "Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 13, "checked": 12, "contradictions": 0, "explained": 0, "papers": 2, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "acns0331", "name": "COG ACNS0331", "nct": "NCT00085735", "corpus": { "status": "mixed", "phase": "3", "enrolled": 549, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT00085735", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 549, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-03-31", "completion": "2024-12-31", "lastUpdate": "2026-06-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "convert", "name": "CONVERT", "nct": "NCT00433563", "corpus": { "status": "mixed", "phase": "3", "enrolled": 547, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT00433563", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 547, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-02", "completion": "2019-01", "lastUpdate": "2022-09-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "cross", "name": "CROSS", "nct": "NTR487", "corpus": { "status": "positive", "phase": "3", "enrolled": 366, "enrolledBasis": "registry", "yearReported": 2012 }, "registry": null, "contradictions": [], "explained": [], "papers": [ { "pmid": "42774476", "doi": "10.1002/fsn3.72380", "title": "<i>Citrus reticulata</i> Essential Oil as a Bioactive Food Ingredient: Composition Variability, Extraction, Functional Bioactivities, and Cross-Study Quantitative Analysis.", "journal": "Food Sci Nutr", "date": "2026-09-21" }, { "pmid": "42793307", "doi": "10.3390/cimb48090951", "title": "Shared and Disease-Preferential Matrisome Programs in Fibrosing Interstitial Lung Disease: Evidence from Cross-Cohort and Within-Cohort Analysis.", "journal": "Curr Issues Mol Biol", "date": "2026-09-17" } ] }, { "id": "eortc-26981", "name": "EORTC 26981 / NCIC CE.3 (Stupp trial)", "nct": "NCT00006353", "corpus": { "status": "positive", "phase": "3", "enrolled": 575, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": { "nct": "NCT00006353", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 575, "enrolmentType": "ACTUAL", "primaryCompletion": "2002-03", "lastUpdate": "2012-09-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "estimabl2", "name": "ESTIMABL2", "nct": "NCT01837745", "corpus": { "status": "positive", "phase": "3", "enrolled": 776, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT01837745", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 776, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-04-01", "completion": "2030-01-01", "lastUpdate": "2023-05-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interlace", "name": "INTERLACE", "nct": "NCT01566240", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT01566240", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02", "completion": "2026-12", "lastUpdate": "2024-12-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "javelin-hn-100", "name": "JAVELIN Head and Neck 100", "nct": "NCT02952586", "corpus": { "status": "negative", "phase": "3", "enrolled": 697, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02952586", "status": "TERMINATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 697, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-12-23", "completion": "2020-08-25", "lastUpdate": "2021-09-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-a18", "name": "KEYNOTE-A18 / ENGOT-cx11 / GOG-3047", "nct": "NCT04221945", "corpus": { "status": "positive", "phase": "3", "enrolled": 1060, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04221945", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1060, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-07", "completion": "2026-01-26", "lastUpdate": "2026-02-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "laura", "name": "LAURA", "nct": "NCT03521154", "corpus": { "status": "positive", "phase": "3", "enrolled": 216, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03521154", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 216, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-05", "completion": "2027-10-29", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nrg-hn002-hn005", "name": "NRG-HN002 & NRG-HN005 (HPV+ de-escalation)", "nct": "NCT03952585", "corpus": { "status": "mixed", "phase": "2/3", "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT03952585", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 384, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-01", "completion": "2026-12-11", "lastUpdate": "2026-07-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "pacific", "name": "PACIFIC", "nct": "NCT02125461", "corpus": { "status": "positive", "phase": "3", "enrolled": 713, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02125461", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 713, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-02-13", "completion": "2023-08-24", "lastUpdate": "2023-10-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "portec-3", "name": "PORTEC-3", "nct": "NCT00411138", "corpus": { "status": "positive", "phase": "3", "enrolled": 660, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00411138", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 670, "enrolmentType": "ESTIMATED", "primaryCompletion": "2018-11-29", "completion": "2024-12-31", "lastUpdate": "2023-10-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "trilynx", "name": "TrilynX", "nct": "NCT04459715", "corpus": { "status": "negative", "phase": "3", "enrolled": 730, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04459715", "status": "TERMINATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 730, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-09-18", "completion": "2024-09-18", "lastUpdate": "2025-10-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "survivorship-roadmap", "name": "Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 6, "checked": 4, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "challenge", "name": "CHALLENGE (CCTG CO.21)", "nct": "NCT00819208", "corpus": { "status": "positive", "phase": "3", "enrolled": 889, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT00819208", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 889, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-07", "completion": "2026-03-17", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ccss", "name": "Childhood Cancer Survivor Study (CCSS)", "nct": "NCT01120353", "corpus": { "status": "active", "phase": "observational", "enrolled": 50000, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01120353", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 50000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-11", "completion": "2026-11", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olanzapine-appetite-tmh", "name": "Low-dose olanzapine for cancer anorexia (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 124, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "ponsegromab-phase-2", "name": "Ponsegromab phase 2 in cancer cachexia", "nct": "NCT05546476", "corpus": { "status": "positive", "phase": "2", "enrolled": 187, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05546476", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 187, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-13", "completion": "2025-04-23", "lastUpdate": "2026-06-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prehab-trial", "name": "PREHAB: multimodal prehabilitation before colorectal cancer surgery", "corpus": { "status": "positive", "phase": "3", "enrolled": 251, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "romana-1-2", "name": "ROMANA 1 and ROMANA 2", "nct": "NCT01387269", "corpus": { "status": "mixed", "phase": "3", "enrolled": 979, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01387269", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 484, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-01", "completion": "2015-02", "lastUpdate": "2017-10-27" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "surgery-roadmap", "name": "Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 22, "checked": 20, "contradictions": 0, "explained": 5, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "azur-1", "name": "AZUR-1", "nct": "NCT05723562", "corpus": { "status": "positive", "phase": "2", "enrolled": 154, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT05723562", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 154, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-11-02", "completion": "2029-10-11", "lastUpdate": "2026-05-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-816", "name": "CheckMate 816", "nct": "NCT02998528", "corpus": { "status": "positive", "phase": "3", "enrolled": 358, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 505 participants (actual) across all arms, including nivolumab plus ipilimumab; the NEJM 2022 primary analysis compared 179 patients randomised to nivolumab plus chemotherapy with 179 randomised to chemotherapy.", "yearReported": 2022 }, "registry": { "nct": "NCT02998528", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 505, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-09-08", "completion": "2024-12-06", "lastUpdate": "2026-01-06" }, "contradictions": [], "explained": [ "enrolment 358 in the corpus (randomised), 505 on the registry (actual; 29 percent apart): ClinicalTrials.gov lists 505 participants (actual) across all arms, including nivolumab plus ipilimumab; the NEJM 2022 primary analysis compared 179 patients randomised to nivolumab plus chemotherapy with 179 randomised to chemotherapy." ], "papers": [] }, { "id": "destiny-breast11", "name": "DESTINY-Breast11", "nct": "NCT05113251", "corpus": { "status": "positive", "phase": "3", "enrolled": 927, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05113251", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 927, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-12", "completion": "2027-04-30", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "nct": "NCT00193765", "corpus": { "status": "positive", "phase": "3", "enrolled": 596, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed.", "yearReported": 2015 }, "registry": { "nct": "NCT00193765", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 710, "enrolmentType": "ESTIMATED", "primaryCompletion": "2019-06", "completion": "2019-06", "lastUpdate": "2017-06-16" }, "contradictions": [], "explained": [ "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." ], "papers": [] }, { "id": "emerald-1", "name": "EMERALD-1", "nct": "NCT03778957", "corpus": { "status": "mixed", "phase": "3", "enrolled": 616, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 724 participants (actual); the Lancet 2025 paper reports 887 patients screened and 616 randomised (204, 207 and 205 across the three arms).", "yearReported": 2024 }, "registry": { "nct": "NCT03778957", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 724, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-09-11", "completion": "2026-08-31", "lastUpdate": "2026-07-15" }, "contradictions": [], "explained": [ "enrolment 616 in the corpus (randomised), 724 on the registry (actual; 15 percent apart): ClinicalTrials.gov lists 724 participants (actual); the Lancet 2025 paper reports 887 patients screened and 616 randomised (204, 207 and 205 across the three arms)." ], "papers": [] }, { "id": "estimabl2", "name": "ESTIMABL2", "nct": "NCT01837745", "corpus": { "status": "positive", "phase": "3", "enrolled": 776, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT01837745", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 776, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-04-01", "completion": "2030-01-01", "lastUpdate": "2023-05-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "fires-sentor", "name": "FIRES & SENTOR (sentinel node mapping)", "nct": "NCT01673022", "corpus": { "status": "positive", "phase": "observational", "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01673022", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 430, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-01", "completion": "2017-01", "lastUpdate": "2018-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-671", "name": "KEYNOTE-671", "nct": "NCT03425643", "corpus": { "status": "positive", "phase": "3", "enrolled": 797, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03425643", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 797, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-07-10", "completion": "2026-10-15", "lastUpdate": "2026-07-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "lacc", "name": "LACC (Laparoscopic Approach to Cervical Cancer)", "nct": "NCT00614211", "corpus": { "status": "negative", "phase": "3", "enrolled": 636, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00614211", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 636, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-03", "completion": "2022-03", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mars-2", "name": "MARS 2", "nct": "NCT02040272", "corpus": { "status": "negative", "phase": "3", "enrolled": 335, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT02040272", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 328, "enrolmentType": "ESTIMATED", "primaryCompletion": "2020-09", "completion": "2022-09", "lastUpdate": "2019-10-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "matterhorn", "name": "MATTERHORN", "nct": "NCT04592913", "corpus": { "status": "positive", "phase": "3", "enrolled": 957, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04592913", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 957, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-12-20", "completion": "2027-09-27", "lastUpdate": "2025-12-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mslt-ii", "name": "MSLT-II", "nct": "NCT00297895", "corpus": { "status": "positive", "phase": "3", "enrolled": 1939, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT00297895", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 1939, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-09-30", "completion": "2019-09-30", "lastUpdate": "2022-05-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nadina", "name": "NADINA", "nct": "NCT04949113", "corpus": { "status": "positive", "phase": "3", "enrolled": 423, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04949113", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 423, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-12", "completion": "2028-12-19", "lastUpdate": "2024-03-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niagara", "name": "NIAGARA", "nct": "NCT03732677", "corpus": { "status": "positive", "phase": "3", "enrolled": 1063, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03732677", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1063, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-04-29", "completion": "2027-11-08", "lastUpdate": "2026-07-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niche-2", "name": "NICHE-2", "nct": "NCT03026140", "corpus": { "status": "positive", "phase": "2", "enrolled": 115, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03026140", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 353, "enrolmentType": "ESTIMATED", "primaryCompletion": "2032-03-01", "completion": "2032-03-01", "lastUpdate": "2026-09-30" }, "contradictions": [], "explained": [ "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." ], "papers": [] }, { "id": "ovhipec-1", "name": "OVHIPEC-1", "nct": "NCT00426257", "corpus": { "status": "positive", "phase": "3", "enrolled": 245, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00426257", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 242, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-08-16", "completion": "2017-08-16", "lastUpdate": "2018-08-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prehab-trial", "name": "PREHAB: multimodal prehabilitation before colorectal cancer surgery", "corpus": { "status": "positive", "phase": "3", "enrolled": 251, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "preopanc", "name": "PREOPANC-1", "nct": "NTR3709", "corpus": { "status": "mixed", "phase": "3", "enrolled": 246, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "sano", "name": "SANO", "nct": "NCT05953181", "corpus": { "status": "positive", "phase": "3", "enrolled": 309, "enrolledBasis": "analysed", "enrolledNote": "ClinicalTrials.gov lists 776 participants (actual); the Lancet Oncology 2025 paper reports 1,115 individuals screened and 309 included in the analysis (198 active surveillance, 111 standard surgery).", "yearReported": 2023 }, "registry": { "nct": "NCT05953181", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 776, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-06-01", "completion": "2026-06-01", "lastUpdate": "2024-09-19" }, "contradictions": [], "explained": [ "enrolment 309 in the corpus (analysed), 776 on the registry (actual; 60 percent apart): ClinicalTrials.gov lists 776 participants (actual); the Lancet Oncology 2025 paper reports 1,115 individuals screened and 309 included in the analysis (198 active surveillance, 111 standard surgery)." ], "papers": [] }, { "id": "senticol-iii", "name": "SENTICOL III", "nct": "NCT03386734", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT03386734", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 989, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-05", "completion": "2029-05", "lastUpdate": "2024-07-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "swog-s1801", "name": "SWOG S1801", "nct": "NCT03698019", "corpus": { "status": "positive", "phase": "2", "enrolled": 313, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03698019", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 313, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-09-01", "completion": "2026-10-30", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "checkmate-816", "name": "CheckMate 816", "text": "enrolment 358 in the corpus (randomised), 505 on the registry (actual; 29 percent apart): ClinicalTrials.gov lists 505 participants (actual) across all arms, including nivolumab plus ipilimumab; the NEJM 2022 primary analysis compared 179 patients randomised to nivolumab plus chemotherapy with 179 randomised to chemotherapy." }, { "ref": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "text": "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." }, { "ref": "emerald-1", "name": "EMERALD-1", "text": "enrolment 616 in the corpus (randomised), 724 on the registry (actual; 15 percent apart): ClinicalTrials.gov lists 724 participants (actual); the Lancet 2025 paper reports 887 patients screened and 616 randomised (204, 207 and 205 across the three arms)." }, { "ref": "niche-2", "name": "NICHE-2", "text": "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." }, { "ref": "sano", "name": "SANO", "text": "enrolment 309 in the corpus (analysed), 776 on the registry (actual; 60 percent apart): ClinicalTrials.gov lists 776 participants (actual); the Lancet Oncology 2025 paper reports 1,115 individuals screened and 309 included in the analysis (198 active surveillance, 111 standard surgery)." } ] }, { "id": "targeted-therapy-roadmap", "name": "Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 27, "checked": 25, "contradictions": 0, "explained": 1, "papers": 3, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "adaura", "name": "ADAURA", "nct": "NCT02511106", "corpus": { "status": "positive", "phase": "3", "enrolled": 682, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02511106", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 682, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-04-11", "completion": "2029-01-31", "lastUpdate": "2026-09-11" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42732874", "doi": "10.1016/j.jtho.2026.104179", "title": "Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].", "journal": "J Thorac Oncol", "date": "2026-09-13" } ] }, { "id": "alina", "name": "ALINA", "nct": "NCT03456076", "corpus": { "status": "positive", "phase": "3", "enrolled": 257, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03456076", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 257, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-06-26", "completion": "2031-11-19", "lastUpdate": "2026-07-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "alkove-1", "name": "ALKOVE-1", "nct": "NCT05384626", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 840, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05384626", "status": "RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 840, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12", "completion": "2028-01", "lastUpdate": "2026-05-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bruin-cll-321", "name": "BRUIN CLL-321", "nct": "NCT04666038", "corpus": { "status": "positive", "phase": "3", "enrolled": 238, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04666038", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 238, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-29", "completion": "2027-05", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "cadance-304", "name": "CaDAnCe-304", "corpus": { "status": "recruiting", "phase": "3", "enrolledBasis": "registry" }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "codebreak-200", "name": "CodeBreaK 200", "nct": "NCT04303780", "corpus": { "status": "positive", "phase": "3", "enrolled": 345, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT04303780", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 345, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-08-02", "completion": "2026-06-24", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "codebreak-300", "name": "CodeBreaK 300", "nct": "NCT05198934", "corpus": { "status": "positive", "phase": "3", "enrolled": 160, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT05198934", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 160, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-16", "completion": "2026-04-14", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "combi-ad", "name": "COMBI-AD", "nct": "NCT01682083", "corpus": { "status": "positive", "phase": "3", "enrolled": 870, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01682083", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 870, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-06-30", "completion": "2023-07-31", "lastUpdate": "2026-04-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dreamseq", "name": "DREAMseq (ECOG-ACRIN EA6134)", "nct": "NCT02224781", "corpus": { "status": "positive", "phase": "3", "enrolled": 267, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02224781", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 267, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-09-30", "completion": "2026-12-19", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "flaura2", "name": "FLAURA2", "nct": "NCT04035486", "corpus": { "status": "positive", "phase": "3", "enrolled": 587, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04035486", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 587, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-04-03", "completion": "2027-09-30", "lastUpdate": "2026-09-03" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42728193", "doi": "10.1016/j.lungcan.2026.109588", "title": "Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.", "journal": "Lung Cancer", "date": "2026-09-14" } ] }, { "id": "gefitinib-chemo-tmh", "name": "Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 350, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "hera-b31-n9831", "name": "HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)", "nct": "NCT00045032", "corpus": { "status": "positive", "phase": "3", "enrolled": 9000, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": { "nct": "NCT00045032", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5099, "enrolmentType": "ACTUAL", "primaryCompletion": "2005-03", "completion": "2015-06", "lastUpdate": "2017-04-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "insight-gist", "name": "INSIGHT", "nct": "NCT05734105", "corpus": { "status": "active", "phase": "3", "enrolled": 54, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05734105", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 54, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12", "completion": "2028-12", "lastUpdate": "2025-12-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "krascendo-1", "name": "Krascendo 1", "nct": "NCT06497556", "corpus": { "status": "positive", "phase": "3", "enrolled": 338, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06497556", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 338, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-05-19", "completion": "2029-11-30", "lastUpdate": "2026-09-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "krystal-12", "name": "KRYSTAL-12", "nct": "NCT04685135", "corpus": { "status": "positive", "phase": "3", "enrolled": 453, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04685135", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 453, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-12-30", "completion": "2026-10-30", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42745627", "doi": "10.1080/14796694.2026.2719409", "title": "Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS<sup>G12C</sup> mutations.", "journal": "Future Oncol", "date": "2026-09-16" } ] }, { "id": "laura", "name": "LAURA", "nct": "NCT03521154", "corpus": { "status": "positive", "phase": "3", "enrolled": 216, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03521154", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 216, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-05", "completion": "2027-10-29", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "libretto-431", "name": "LIBRETTO-431", "nct": "NCT04194944", "corpus": { "status": "positive", "phase": "3", "enrolled": 261, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04194944", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 261, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-05-01", "completion": "2030-06", "lastUpdate": "2025-10-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "litespark-005", "name": "LITESPARK-005", "nct": "NCT04195750", "corpus": { "status": "positive", "phase": "3", "enrolled": 755, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04195750", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 755, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-04-15", "completion": "2026-09-17", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mariposa", "name": "MARIPOSA", "nct": "NCT04487080", "corpus": { "status": "positive", "phase": "3", "enrolled": 1074, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04487080", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1074, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-11", "completion": "2028-02-16", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olympia", "name": "OlympiA", "nct": "NCT02032823", "corpus": { "status": "positive", "phase": "3", "enrolled": 1837, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02032823", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1837, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-27", "completion": "2029-05-28", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "profound", "name": "PROfound", "nct": "NCT02987543", "corpus": { "status": "positive", "phase": "3", "enrolled": 387, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02987543", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 387, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-06-04", "completion": "2023-02-15", "lastUpdate": "2023-10-06" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rasolute-302", "name": "RASolute 302", "nct": "NCT06625320", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06625320", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06", "completion": "2027-12", "lastUpdate": "2026-06-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-09-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "solo-1", "name": "SOLO-1", "nct": "NCT01844986", "corpus": { "status": "positive", "phase": "3", "enrolled": 391, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 450 participants (actual); the NEJM 2018 primary analysis randomised 391 patients (260 olaparib, 131 placebo).", "yearReported": 2018 }, "registry": { "nct": "NCT01844986", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 450, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-05-17", "completion": "2028-08-29", "lastUpdate": "2025-12-10" }, "contradictions": [], "explained": [ "enrolment 391 in the corpus (randomised), 450 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 450 participants (actual); the NEJM 2018 primary analysis randomised 391 patients (260 olaparib, 131 placebo)." ], "papers": [] }, { "id": "telimet-nsclc-01", "name": "TeliMET NSCLC-01", "nct": "NCT04928846", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 768, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04928846", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 768, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-12", "completion": "2029-02", "lastUpdate": "2026-09-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "toga", "name": "ToGA", "nct": "NCT01041404", "corpus": { "status": "positive", "phase": "3", "enrolled": 594, "enrolledBasis": "registry", "yearReported": 2010 }, "registry": { "nct": "NCT01041404", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 584, "enrolmentType": "ACTUAL", "primaryCompletion": "2010-06", "completion": "2010-06", "lastUpdate": "2014-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "veritac-2", "name": "VERITAC-2", "nct": "NCT05654623", "corpus": { "status": "mixed", "phase": "3", "enrolled": 624, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05654623", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 624, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-31", "completion": "2028-05-15", "lastUpdate": "2026-03-18" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "solo-1", "name": "SOLO-1", "text": "enrolment 391 in the corpus (randomised), 450 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 450 participants (actual); the NEJM 2018 primary analysis randomised 391 patients (260 olaparib, 131 placebo)." } ] }, { "id": "tnbc-history", "name": "TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 14, "checked": 14, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent", "name": "ASCENT", "nct": "NCT02574455", "corpus": { "status": "positive", "phase": "3", "enrolled": 529, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02574455", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 529, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-30", "completion": "2020-12-08", "lastUpdate": "2022-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ascent-03", "name": "ASCENT-03", "nct": "NCT05382299", "corpus": { "status": "positive", "phase": "3", "enrolled": 558, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients.", "yearReported": 2025 }, "registry": { "nct": "NCT05382299", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 623, "enrolmentType": "ACTUAL", "primaryCompletion": "2028-07", "completion": "2028-07", "lastUpdate": "2026-04-06" }, "contradictions": [], "explained": [ "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." ], "papers": [] }, { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bl-b01d1-307", "name": "BL-B01D1-307", "nct": "NCT06382142", "corpus": { "status": "positive", "phase": "3", "enrolled": 418, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06382142", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 418, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-13", "completion": "2027-12", "lastUpdate": "2026-07-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast04", "name": "DESTINY-Breast04", "nct": "NCT03734029", "corpus": { "status": "positive", "phase": "3", "enrolled": 557, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03734029", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 557, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-01-11", "completion": "2026-05-19", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "impassion130", "name": "IMpassion130", "nct": "NCT02425891", "corpus": { "status": "mixed", "phase": "3", "enrolled": 902, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT02425891", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 902, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-04-14", "completion": "2021-08-31", "lastUpdate": "2022-07-19" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "izabright-breast01", "name": "IZABRIGHT-Breast01", "nct": "NCT06926868", "corpus": { "status": "recruiting", "phase": "2/3", "enrolled": 570, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06926868", "status": "RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-03-13", "completion": "2030-05-15", "lastUpdate": "2026-08-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-355", "name": "KEYNOTE-355", "nct": "NCT02819518", "corpus": { "status": "positive", "phase": "3", "enrolled": 882, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02819518", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 882, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-06-15", "completion": "2023-10-30", "lastUpdate": "2024-11-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olympia", "name": "OlympiA", "nct": "NCT02032823", "corpus": { "status": "positive", "phase": "3", "enrolled": 1837, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02032823", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1837, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-27", "completion": "2029-05-28", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "optimice-pcr", "name": "OptimICE-pCR (A012103)", "nct": "NCT05812807", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 1295, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05812807", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1295, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-05-31", "completion": "2033-05-31", "lastUpdate": "2026-08-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "scarlet-s2212", "name": "SCARLET (SWOG S2212)", "nct": "NCT05929768", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 2400, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05929768", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2400, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-03-31", "completion": "2033-04", "lastUpdate": "2025-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast02", "name": "TROPION-Breast02", "nct": "NCT05374512", "corpus": { "status": "positive", "phase": "3", "enrolled": 644, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05374512", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 644, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-25", "completion": "2026-12-31", "lastUpdate": "2026-05-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast05", "name": "TROPION-Breast05", "nct": "NCT06103864", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 625, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06103864", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 625, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-07-28", "completion": "2030-09-30", "lastUpdate": "2026-09-25" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "ascent-03", "name": "ASCENT-03", "text": "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." } ] }, { "id": "trial-modernisation-roadmap", "name": "Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 12, "checked": 10, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "add-aspirin", "name": "Add-Aspirin", "nct": "NCT02804815", "corpus": { "status": "active", "phase": "3", "enrolled": 11000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT02804815", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-10", "completion": "2026-10", "lastUpdate": "2025-06-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "challenge", "name": "CHALLENGE (CCTG CO.21)", "nct": "NCT00819208", "corpus": { "status": "positive", "phase": "3", "enrolled": 889, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT00819208", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 889, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-07", "completion": "2026-03-17", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "imvigor011", "name": "IMvigor011", "nct": "NCT04660344", "corpus": { "status": "positive", "phase": "3", "enrolled": 761, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04660344", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 761, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-15", "completion": "2026-10-01", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "pediatric-match", "name": "NCI-COG Pediatric MATCH (APEC1621)", "nct": "NCT03155620", "corpus": { "status": "active", "phase": "platform", "enrolled": 1377, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03155620", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 1377, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-31", "completion": "2027-01-06", "lastUpdate": "2026-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niche-2", "name": "NICHE-2", "nct": "NCT03026140", "corpus": { "status": "positive", "phase": "2", "enrolled": 115, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03026140", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 353, "enrolmentType": "ESTIMATED", "primaryCompletion": "2032-03-01", "completion": "2032-03-01", "lastUpdate": "2026-09-30" }, "contradictions": [], "explained": [ "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." ], "papers": [] }, { "id": "persephone", "name": "PERSEPHONE", "nct": "NCT00712140", "corpus": { "status": "positive", "phase": "3", "enrolled": 4088, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT00712140", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 4000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2011-10", "lastUpdate": "2011-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "phergain", "name": "PHERGain", "nct": "NCT03161353", "corpus": { "status": "positive", "phase": "2", "enrolled": 377, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03161353", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 377, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-11-01", "completion": "2026-11-01", "lastUpdate": "2025-04-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-09-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "stampede", "name": "STAMPEDE", "nct": "NCT00268476", "corpus": { "status": "positive", "phase": "platform", "enrolled": 11992, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00268476", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-03", "completion": "2030-12", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "niche-2", "name": "NICHE-2", "text": "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." } ] }, { "id": "tnbc-roadmap", "name": "Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem", "asOf": "2026-09-24", "since": "2026-09-24", "counts": { "trials": 25, "checked": 25, "contradictions": 1, "explained": 1, "papers": 0, "watch": 13, "watchPassed": 1 }, "trials": [ { "id": "ascent", "name": "ASCENT", "nct": "NCT02574455", "corpus": { "status": "positive", "phase": "3", "enrolled": 529, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02574455", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 529, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-30", "completion": "2020-12-08", "lastUpdate": "2022-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ascent-03", "name": "ASCENT-03", "nct": "NCT05382299", "corpus": { "status": "positive", "phase": "3", "enrolled": 558, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients.", "yearReported": 2025 }, "registry": { "nct": "NCT05382299", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 623, "enrolmentType": "ACTUAL", "primaryCompletion": "2028-07", "completion": "2028-07", "lastUpdate": "2026-04-06" }, "contradictions": [], "explained": [ "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." ], "papers": [] }, { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ascent-05", "name": "ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)", "nct": "NCT05633654", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 1514, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05633654", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1514, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-06", "completion": "2031-08", "lastUpdate": "2026-09-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bl-b01d1-307", "name": "BL-B01D1-307", "nct": "NCT06382142", "corpus": { "status": "positive", "phase": "3", "enrolled": 418, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06382142", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 418, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-13", "completion": "2027-12", "lastUpdate": "2026-07-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "brightness", "name": "BrighTNess", "nct": "NCT02032277", "corpus": { "status": "completed", "phase": "3", "enrolled": 634, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT02032277", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 634, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-03-18", "completion": "2020-11-12", "lastUpdate": "2021-01-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct03997123", "name": "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC", "nct": "NCT03997123", "corpus": { "status": "active", "phase": "3", "enrolled": 923, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 923 participants (actual); the Annals of Oncology 2026 primary paper covers 812 randomised patients.", "yearReported": 2026 }, "registry": { "nct": "NCT03997123", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 923, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-03-16", "completion": "2026-03-16", "lastUpdate": "2025-12-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast04", "name": "DESTINY-Breast04", "nct": "NCT03734029", "corpus": { "status": "positive", "phase": "3", "enrolled": 557, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03734029", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 557, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-01-11", "completion": "2026-05-19", "lastUpdate": "2026-09-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "embraca", "name": "EMBRACA", "nct": "NCT01945775", "corpus": { "status": "positive", "phase": "3", "enrolled": 431, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01945775", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 431, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-09-15", "completion": "2021-03-05", "lastUpdate": "2022-01-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "geparsixto", "name": "GeparSixto", "nct": "NCT01426880", "corpus": { "status": "positive", "phase": "2/3", "enrolled": 595, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": { "nct": "NCT01426880", "status": "COMPLETED", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 595, "enrolmentType": "ACTUAL", "primaryCompletion": "2013-05", "completion": "2013-08", "lastUpdate": "2016-02-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "impassion031", "name": "IMpassion031", "nct": "NCT03197935", "corpus": { "status": "positive", "phase": "3", "enrolled": 333, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03197935", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 333, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-04-03", "completion": "2022-09-28", "lastUpdate": "2023-10-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "impassion130", "name": "IMpassion130", "nct": "NCT02425891", "corpus": { "status": "mixed", "phase": "3", "enrolled": 902, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT02425891", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 902, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-04-14", "completion": "2021-08-31", "lastUpdate": "2022-07-19" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "impassion131", "name": "IMpassion131", "nct": "NCT03125902", "corpus": { "status": "negative", "phase": "3", "enrolled": 653, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03125902", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 653, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-11-15", "completion": "2023-01-17", "lastUpdate": "2024-03-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "izabright-breast01", "name": "IZABRIGHT-Breast01", "nct": "NCT06926868", "corpus": { "status": "recruiting", "phase": "2/3", "enrolled": 570, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06926868", "status": "RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-03-13", "completion": "2030-05-15", "lastUpdate": "2026-08-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-355", "name": "KEYNOTE-355", "nct": "NCT02819518", "corpus": { "status": "positive", "phase": "3", "enrolled": 882, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02819518", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 882, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-06-15", "completion": "2023-10-30", "lastUpdate": "2024-11-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olympia", "name": "OlympiA", "nct": "NCT02032823", "corpus": { "status": "positive", "phase": "3", "enrolled": 1837, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02032823", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1837, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-27", "completion": "2029-05-28", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olympiad", "name": "OlympiAD", "nct": "NCT02000622", "corpus": { "status": "positive", "phase": "3", "enrolled": 302, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02000622", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 302, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-12-09", "completion": "2025-12-23", "lastUpdate": "2026-02-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "optimice-pcr", "name": "OptimICE-pCR (A012103)", "nct": "NCT05812807", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 1295, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05812807", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1295, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-05-31", "completion": "2033-05-31", "lastUpdate": "2026-08-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nct06419621", "name": "PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC", "nct": "NCT06419621", "corpus": { "status": "active", "phase": "3", "enrolled": 392, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06419621", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 392, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-07", "completion": "2028-07", "lastUpdate": "2026-07-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "scarlet-s2212", "name": "SCARLET (SWOG S2212)", "nct": "NCT05929768", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 2400, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05929768", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2400, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-03-31", "completion": "2033-04", "lastUpdate": "2025-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast01", "name": "TROPION-Breast01", "nct": "NCT05104866", "corpus": { "status": "mixed", "phase": "3", "enrolled": 732, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT05104866", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 732, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-07-24", "completion": "2026-12-31", "lastUpdate": "2026-08-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast02", "name": "TROPION-Breast02", "nct": "NCT05374512", "corpus": { "status": "positive", "phase": "3", "enrolled": 644, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05374512", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 644, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-25", "completion": "2026-12-31", "lastUpdate": "2026-05-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast03", "name": "TROPION-Breast03", "nct": "NCT05629585", "corpus": { "status": "active", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05629585", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-09-20", "completion": "2030-01-30", "lastUpdate": "2026-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast05", "name": "TROPION-Breast05", "nct": "NCT06103864", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 625, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06103864", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 625, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-07-28", "completion": "2030-09-30", "lastUpdate": "2026-09-25" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "TROPION-Breast02 study completion on the registry (datopotamab deruxtecan first line, immunotherapy-ineligible; primary completion 25 August 2025, actual)", "expected": "2026-12-31", "source": "https://clinicaltrials.gov/study/NCT05374512", "refs": [ "tropion-breast02", "datopotamab-deruxtecan" ], "passed": false, "contradictions": [] }, { "item": "CAPItello-290 study completion on the registry (capivasertib plus paclitaxel first line; published negative for overall survival in 2026)", "expected": "2026-03-16", "source": "https://clinicaltrials.gov/study/NCT03997123", "refs": [ "nct03997123", "capivasertib", "paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026" ], "passed": true, "contradictions": [] }, { "item": "ASCENT-05 / OptimICE-RD primary completion: sacituzumab govitecan with pembrolizumab vs physician's choice for residual invasive disease after neoadjuvant therapy (1,514 estimated participants)", "expected": "2027-06", "source": "https://clinicaltrials.gov/study/NCT05633654", "refs": [ "ascent-05", "sacituzumab-govitecan", "pembrolizumab", "rcb" ], "passed": false, "contradictions": [] }, { "item": "TROPION-Breast05 primary completion: datopotamab deruxtecan with or without durvalumab vs chemotherapy with pembrolizumab, first line, PD-L1-positive (625 estimated participants)", "expected": "2027-07-28", "source": "https://clinicaltrials.gov/study/NCT06103864", "refs": [ "tropion-breast05", "datopotamab-deruxtecan", "cps" ], "passed": false, "contradictions": [] }, { "item": "PM8002 (PD-L1 and VEGF bispecific) plus nab-paclitaxel vs placebo plus nab-paclitaxel, first line: primary completion (392 estimated participants)", "expected": "2027-07", "source": "https://clinicaltrials.gov/study/NCT06419621", "refs": [ "nct06419621", "nab-paclitaxel" ], "passed": false, "contradictions": [] }, { "item": "TROPION-Breast03 primary completion: datopotamab deruxtecan with or without durvalumab vs investigator's choice for stage I to III disease without pathological complete response (1,174 participants; active, not recruiting)", "expected": "2027-09-20", "source": "https://clinicaltrials.gov/study/NCT05629585", "refs": [ "tropion-breast03", "datopotamab-deruxtecan", "rcb" ], "passed": false, "contradictions": [] }, { "item": "BL-B01D1-307 / PANKU-Breast02 study completion (izalontamab brengitecan vs chemotherapy in pretreated disease; primary completion 13 January 2026, actual)", "expected": "2027-12", "source": "https://clinicaltrials.gov/study/NCT06382142", "refs": [ "bl-b01d1-307", "izalontamab-brengitecan" ], "passed": false, "contradictions": [] }, { "item": "IZABRIGHT-Breast01 primary completion: izalontamab brengitecan vs chemotherapy, first line, anti-PD-(L)1-ineligible (600 estimated participants)", "expected": "2028-03-13", "source": "https://clinicaltrials.gov/study/NCT06926868", "refs": [ "izabright-breast01", "izalontamab-brengitecan", "bispecific-adc" ], "passed": false, "contradictions": [] }, { "item": "OlympiA study completion on the registry (adjuvant olaparib; primary completion 27 March 2020, actual; six-year update published 2026)", "expected": "2029-05-28", "source": "https://clinicaltrials.gov/study/NCT02032823", "refs": [ "olympia", "olaparib", "paper-olympia-6-year-update-ann-oncol-2026" ], "passed": false, "contradictions": [] }, { "item": "SCARLET (S2212) primary completion: shorter anthracycline-free chemo-immunotherapy vs the KEYNOTE-522 regimen (2,400 estimated participants)", "expected": "2033-03-31", "source": "https://clinicaltrials.gov/study/NCT05929768", "refs": [ "scarlet-s2212", "keynote-522", "anthracycline", "de-escalation" ], "passed": false, "contradictions": [ "KEYNOTE-522: watch item expects 2033-03-31; the registry now lists primary completion 2025-10-14 and completion 2025-10-14" ] }, { "item": "OptimICE-pCR primary completion: adjuvant pembrolizumab vs observation after pathological complete response to chemotherapy plus pembrolizumab (1,295 estimated participants)", "expected": "2033-05-31", "source": "https://clinicaltrials.gov/study/NCT05812807", "refs": [ "optimice-pcr", "pembrolizumab", "pcr", "de-escalation" ], "passed": false, "contradictions": [] }, { "item": "A randomised trial of antibody-drug conjugate sequence (TROP2 conjugate then trastuzumab deruxtecan or the reverse, with or without chemotherapy between); none found on ClinicalTrials.gov on 24 September 2026", "source": "https://europepmc.org/article/MED/41937088", "refs": [ "adc-sequencing", "idea-tnbc-adc-sequencing-trial" ], "passed": false, "contradictions": [] }, { "item": "A ctDNA-guided adjuvant trial in triple-negative breast cancer with early, tumour-informed sampling that reports after c-TRAK TN; the design lesson is recorded in the 2023 paper", "source": "https://europepmc.org/article/MED/36423745", "refs": [ "ctdna", "mrd-testing", "idea-tnbc-ctdna-guided-adjuvant-decisions" ], "passed": false, "contradictions": [] } ], "contradictions": [ { "ref": "scarlet-s2212", "name": "SCARLET (S2212) primary completion: shorter anthracycline-free chemo-immunotherapy vs the KEYNOTE-522 regimen (2,400 estimated participants)", "text": "KEYNOTE-522: watch item expects 2033-03-31; the registry now lists primary completion 2025-10-14 and completion 2025-10-14" } ], "explained": [ { "ref": "ascent-03", "name": "ASCENT-03", "text": "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." } ] }, { "id": "trop2-adc-roadmap", "name": "TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 7, "checked": 7, "contradictions": 0, "explained": 1, "papers": 1, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent", "name": "ASCENT", "nct": "NCT02574455", "corpus": { "status": "positive", "phase": "3", "enrolled": 529, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02574455", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 529, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-30", "completion": "2020-12-08", "lastUpdate": "2022-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ascent-03", "name": "ASCENT-03", "nct": "NCT05382299", "corpus": { "status": "positive", "phase": "3", "enrolled": 558, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients.", "yearReported": 2025 }, "registry": { "nct": "NCT05382299", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 623, "enrolmentType": "ACTUAL", "primaryCompletion": "2028-07", "completion": "2028-07", "lastUpdate": "2026-04-06" }, "contradictions": [], "explained": [ "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." ], "papers": [] }, { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast01", "name": "TROPION-Breast01", "nct": "NCT05104866", "corpus": { "status": "mixed", "phase": "3", "enrolled": 732, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT05104866", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 732, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-07-24", "completion": "2026-12-31", "lastUpdate": "2026-08-24" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42727418", "doi": "10.1016/j.esmoop.2026.108538", "title": "Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort.", "journal": "ESMO Open", "date": "2026-09-11" } ] }, { "id": "tropion-breast02", "name": "TROPION-Breast02", "nct": "NCT05374512", "corpus": { "status": "positive", "phase": "3", "enrolled": 644, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05374512", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 644, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-25", "completion": "2026-12-31", "lastUpdate": "2026-05-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast05", "name": "TROPION-Breast05", "nct": "NCT06103864", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 625, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06103864", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 625, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-07-28", "completion": "2030-09-30", "lastUpdate": "2026-09-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-lung01", "name": "TROPION-Lung01", "nct": "NCT04656652", "corpus": { "status": "mixed", "phase": "3", "enrolled": 605, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04656652", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 605, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-05-10", "completion": "2027-02-15", "lastUpdate": "2026-08-26" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "ascent-03", "name": "ASCENT-03", "text": "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." } ] }, { "id": "virtual-cell", "name": "Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] } ] }